| 1 |
Das R, Hyer RN, Burton P, Miller JM, Kuter BJ. Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape. Hum Vaccin Immunother 2023;19:2153532. [PMID: 36629006 DOI: 10.1080/21645515.2022.2153532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 2 |
Tu Y, Hayat T, Hobiny A, Meng X. Modeling and multi-objective optimal control of reaction-diffusion COVID-19 system due to vaccination and patient isolation. Appl Math Model 2023;118:556-91. [PMID: 36818395 DOI: 10.1016/j.apm.2023.02.002] [Reference Citation Analysis]
|
| 3 |
He D, Cowling BJ, Ali ST, Stone L. Rapid global spread of variants of concern of SARS-CoV-2. IJID Reg 2023;7:63-5. [PMID: 36569559 DOI: 10.1016/j.ijregi.2022.12.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Petrone D, Mateo-Urdiales A, Sacco C, Riccardo F, Bella A, Ambrosio L, Lo Presti A, Di Martino A, Ceccarelli E, Del Manso M, Fabiani M, Stefanelli P, Pezzotti P, Palamara A; Italian Integrated Surveillance of COVID-19. Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November 2021 - February 2022). Int J Infect Dis 2023;129:135-41. [PMID: 36708869 DOI: 10.1016/j.ijid.2023.01.027] [Reference Citation Analysis]
|
| 5 |
Chen J, Gu C, Ruan Z, Tang M. Competition of SARS-CoV-2 variants on the pandemic transmission dynamics. Chaos Solitons Fractals 2023;169:113193. [PMID: 36817403 DOI: 10.1016/j.chaos.2023.113193] [Reference Citation Analysis]
|
| 6 |
Torii S, Kim KS, Koseki J, Suzuki R, Iwanami S, Fujita Y, Jeong YD, Ito J, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Sato K, Matsuura Y, Shimamura T, Iwami S, Fukuhara T, The Genotype to Phenotype Japan (G2P-Japan) Consortium. Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir. PLoS Pathog 2023;19:e1011231. [DOI: 10.1371/journal.ppat.1011231] [Reference Citation Analysis]
|
| 7 |
Bettinger JA, Irvine MA, Shulha HP, Valiquette L, Muller MP, Vanderkooi OG, Kellner JD, Top KA, Sadarangani M, McGeer A, Isenor JE, Marty K, Soe P, De Serres G; Canadian Immunization Research Network. Adverse Events Following Immunization With mRNA and Viral Vector Vaccines in Individuals With Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection From the Canadian National Vaccine Safety Network. Clin Infect Dis 2023;76:1088-102. [PMID: 36310514 DOI: 10.1093/cid/ciac852] [Reference Citation Analysis]
|
| 8 |
Burkholz S, Rubsamen M, Blankenberg L, Carback RT 3rd, Mochly-Rosen D, Harris PE. Analysis of well-annotated next-generation sequencing data reveals increasing cases of SARS-CoV-2 reinfection with Omicron. Commun Biol 2023;6:288. [PMID: 36934204 DOI: 10.1038/s42003-023-04687-4] [Reference Citation Analysis]
|
| 9 |
Greaney AM, Raredon MSB, Kochugaeva MP, Niklason LE, Levchenko A. SARS-CoV-2 leverages airway epithelial protective mechanism for viral infection. iScience 2023;26:106175. [PMID: 36788793 DOI: 10.1016/j.isci.2023.106175] [Reference Citation Analysis]
|
| 10 |
Le TP, Abell I, Conway E, Campbell PT, Hogan AB, Lydeamore MJ, Mcvernon J, Mueller I, Walker CR, Baker CM. Modelling the impact of hybrid immunity on future COVID-19 epidemic waves.. [DOI: 10.1101/2023.03.12.23287174] [Reference Citation Analysis]
|
| 11 |
Lewnard JA, Hong V, Kim JS, Shaw SF, Lewin B, Takhar H, Lipsitch M, Tartof SY. Increased vaccine sensitivity of an emerging SARS-CoV-2 variant.. [DOI: 10.1101/2023.03.11.23287148] [Reference Citation Analysis]
|
| 12 |
Cui Q, Shi Z, Yimamaidi D, Hu B, Zhang Z, Saqib M, Zohaib A, Gulnara B, Yersyn M, Hu Z, Li S. Dynamic variations in COVID-19 with the SARS-CoV-2 Omicron variant in Kazakhstan and Pakistan. Infect Dis Poverty 2023;12:18. [PMID: 36918974 DOI: 10.1186/s40249-023-01072-5] [Reference Citation Analysis]
|
| 13 |
Gerardi V, Rohaim MA, Naggar RFE, Atasoy MO, Munir M. Deep Structural Analysis of Myriads of Omicron Sub-Variants Revealed Hotspot for Vaccine Escape Immunity. Vaccines 2023;11:668. [DOI: 10.3390/vaccines11030668] [Reference Citation Analysis]
|
| 14 |
COVID-19 Forecasting Team. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet 2023;401:833-42. [PMID: 36930674 DOI: 10.1016/S0140-6736(22)02465-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Cohen C, Pulliam J. COVID-19 infection, reinfection, and the transition to endemicity. Lancet 2023;401:798-800. [PMID: 36930672 DOI: 10.1016/S0140-6736(22)02634-4] [Reference Citation Analysis]
|
| 16 |
Scutari R, Fox V, De Ioris MA, Fini V, Granaglia A, Costabile V, Colagrossi L, Russo C, Mastronuzzi A, Locatelli F, Perno CF, Alteri C. A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia. BMC Infect Dis 2023;23:133. [PMID: 36882724 DOI: 10.1186/s12879-023-08111-4] [Reference Citation Analysis]
|
| 17 |
Anand U, Pal T, Zanoletti A, Sundaramurthy S, Varjani S, Rajapaksha AU, Barceló D, Bontempi E. The spread of the omicron variant: Identification of knowledge gaps, virus diffusion modelling, and future research needs. Environ Res 2023;225:115612. [PMID: 36871942 DOI: 10.1016/j.envres.2023.115612] [Reference Citation Analysis]
|
| 18 |
Chua FJD, Kim SY, Hill E, Cai JW, Lee WL, Gu X, Afri Affandi SA, Kwok WCG, Ng W, Leifels M, Armas F, Chandra F, Chen H, Alm EJ, Tay M, Wong CCJ, Ng LC, Wuertz S, Thompson JR. Co-incidence of BA.1 and BA.2 at the start of Singapore's Omicron wave revealed by Community and University Campus wastewater surveillance. Sci Total Environ 2023;875:162611. [PMID: 36871716 DOI: 10.1016/j.scitotenv.2023.162611] [Reference Citation Analysis]
|
| 19 |
Turbett SE, Tomkins-Tinch CH, Anahtar MN, Dugdale CM, Hyle EP, Shenoy ES, Shaw B, Egbuonu K, Bowman KA, Zachary KC, Adams GC, Hooper DC, Ryan ET, LaRocque RC, Bassett IV, Triant VA, Siddle KJ, Rosenberg E, Sabeti PC, Schaffner SF, MacInnis BL, Lemieux JE, Charles RC. Distinguishing Severe Acute Respiratory Syndrome Coronavirus 2 Persistence and Reinfection: A Retrospective Cohort Study. Clin Infect Dis 2023;76:850-60. [PMID: 36268576 DOI: 10.1093/cid/ciac830] [Reference Citation Analysis]
|
| 20 |
Negar Firouzabadi, Parisa Ghasemiyeh, Fatemeh Moradishooli, Soliman Mohammadi-Samani. Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. Int Immunopharmacol 2023:109968. [ DOI: 10.1016/j.intimp.2023.109968] [Reference Citation Analysis]
|
| 21 |
Bordi L, Sberna G, Lalle E, Fabeni L, Mazzotta V, Lanini S, Corpolongo A, Garbuglia AR, Nicastri E, Girardi E, Vaia F, Antinori A, Maggi F. Comparison of SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples from Patients Infected with Omicron Variant. Int J Mol Sci 2023;24. [PMID: 36902277 DOI: 10.3390/ijms24054847] [Reference Citation Analysis]
|
| 22 |
Abul Y, Leeder C, Gravenstein S. Epidemiology and Clinical Presentation of COVID-19 in Older Adults. Infect Dis Clin North Am 2023;37:1-26. [PMID: 36805007 DOI: 10.1016/j.idc.2022.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Wang B, Andraweera P, Elliott S, Mohammed H, Lassi Z, Twigger A, Borgas C, Gunasekera S, Ladhani S, Marshall HS. Asymptomatic SARS-CoV-2 Infection by Age: A Global Systematic Review and Meta-analysis. Pediatr Infect Dis J 2023;42:232-9. [PMID: 36730054 DOI: 10.1097/INF.0000000000003791] [Reference Citation Analysis]
|
| 24 |
Jin S, Lim JT, Dickens BL, Cook AR. The impact of earlier reopening to travel in the Western Pacific on SARS-CoV-2 transmission. IJID Reg 2023;6:135-41. [PMID: 36466213 DOI: 10.1016/j.ijregi.2022.11.013] [Reference Citation Analysis]
|
| 25 |
Hirotsu Y, Omata M. Genomic evidence for reinfection with different Omicron subvariants. J Infect 2023;86:e61-3. [PMID: 36642191 DOI: 10.1016/j.jinf.2023.01.010] [Reference Citation Analysis]
|
| 26 |
Metzler M, Tharyan RG, Klann K, Grikscheit K, Bojkova D, Cinatl J, Tascher G, Ciesek S, Münch C. SARS-CoV-2 variants show different host cell proteome profiles with delayed immune response activation in Omicron-infected cells. Molecular & Cellular Proteomics 2023. [DOI: 10.1016/j.mcpro.2023.100537] [Reference Citation Analysis]
|
| 27 |
Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nat Rev Microbiol 2023;21:147-61. [PMID: 36460930 DOI: 10.1038/s41579-022-00822-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 28 |
Jubair M, Begum MN, Rahman S, Haider SMA, Moon SB, Hossain ME, Rahman MZ, Khan MH, Alam AN, Shirin T, Afrad MH, Qadri F, Rahman M. SARS-CoV-2 Omicron variants in Bangladesh: Pandemic to endemic. Health Sci Rep 2023;6:e1134. [PMID: 36875934 DOI: 10.1002/hsr2.1134] [Reference Citation Analysis]
|
| 29 |
Hamad M, AlKhamach DMH, Alsayadi LM, Sarhan SA, Saeed BQ, Sokovic M, Ben Hadda T, Soliman SSM. Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy. Viral Immunol 2023;36:83-100. [PMID: 36695729 DOI: 10.1089/vim.2022.0122] [Reference Citation Analysis]
|
| 30 |
Beukenhorst AL, Koch CM, Hadjichrysanthou C, Alter G, de Wolf F, Anderson RM, Goudsmit J. SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies. Eur J Epidemiol 2023;38:237-42. [PMID: 36738380 DOI: 10.1007/s10654-023-00965-x] [Reference Citation Analysis]
|
| 31 |
Heinrich F, Huter T, Mertens S, Lange P, Vering J, Heinemann A, Nörz DS, Hoffmann A, Aepfelbacher M, Ondruschka B, Krasemann S, Lütgehetmann M. New Postmortem Perspective on Emerging SARS-CoV-2 Variants of Concern, Germany. Emerg Infect Dis 2023;29:652-6. [PMID: 36787498 DOI: 10.3201/eid2903.221297] [Reference Citation Analysis]
|
| 32 |
Yang SL, Ripen AM, Lee JV, Koh K, Yen CH, Chand AK, Abdul Rahim NAB, Gokilavanan V, Mohamed NNEB, Sevalingam RKA, Peariasamy KM. Time from last immunity event against infection during Omicron-dominant period in Malaysia. Int J Infect Dis 2023;128:98-101. [PMID: 36581187 DOI: 10.1016/j.ijid.2022.12.025] [Reference Citation Analysis]
|
| 33 |
Ellingson KD, Hollister J, Porter CJ, Khan SM, Feldstein LR, Naleway AL, Gaglani M, Caban-Martinez AJ, Tyner HL, Lowe AA, Olsho LEW, Meece J, Yoon SK, Mak J, Kuntz JL, Solle NS, Respet K, Baccam Z, Wesley MG, Thiese MS, Yoo YM, Odean MJ, Miiro FN, Pickett SL, Phillips AL, Grant L, Romine JK, Herring MK, Hegmann KT, Lamberte JM, Sokol B, Jovel KS, Thompson MG, Rivers P, Pilishvili T, Lutrick K, Burgess JL, Midgley CM, Fowlkes AL. Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers. Emerg Infect Dis 2023;29:599-604. [PMID: 36703252 DOI: 10.3201/eid2903.221314] [Reference Citation Analysis]
|
| 34 |
Petrie JG, King JP, McClure DL, Rolfes MA, Meece JK, Pattinson D, Neumann G, Kawaoka Y, Belongia EA, McLean HQ. Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022. Influenza Other Respir Viruses 2023;17:e13104. [PMID: 36875208 DOI: 10.1111/irv.13104] [Reference Citation Analysis]
|
| 35 |
Qu P, Evans JP, Kurhade C, Zeng C, Zheng YM, Xu K, Shi PY, Xie X, Liu SL. Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants. mBio 2023;14:e0317622. [PMID: 36625591 DOI: 10.1128/mbio.03176-22] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 36 |
Boroojerdi MH, Al Jabry T, Mirarefin SMJ, Albalushi H. Insights into organoid-based modeling of COVID-19 pathology. Virol J 2023;20:37. [PMID: 36841795 DOI: 10.1186/s12985-023-01996-2] [Reference Citation Analysis]
|
| 37 |
Armanious A, Wang H, Alpert PA, Medaglia C, Peydayesh M, Zwygart AC, Gübeli C, Handschin S, Bolisetty S, Ammann M, Tapparel C, Stellacci F, Mezzenga R. Trapping virus-loaded aerosols using granular material composed of protein nanofibrils and iron oxyhydroxides nanoparticles. Front Soft Matter 2023;3. [DOI: 10.3389/frsfm.2023.1143958] [Reference Citation Analysis]
|
| 38 |
Liu Y. Integrative network pharmacology and in silico analyses identify the anti-omicron SARS-CoV-2 potential of eugenol. Heliyon 2023;9:e13853. [PMID: 36845041 DOI: 10.1016/j.heliyon.2023.e13853] [Reference Citation Analysis]
|
| 39 |
Zhu Y, Zhong Q, Ma Z, Liu S, Lan Y, Peng B, Zhang X, Shi X, Qu J, Wu Z, Zhao Z, Zhang X, Zhang D. Neutralization Effect of Sera against Delta and Omicron in Patients Recovering from COVID-19 and Inactivated Vaccine Recipients. Vaccines (Basel) 2023;11. [PMID: 36851348 DOI: 10.3390/vaccines11020471] [Reference Citation Analysis]
|
| 40 |
Spiess K, Gunalan V, Marving E, Nielsen SH, Jørgensen MGP, Fomsgaard AS, Nielsen L, Alfaro-Núñez A, Karst SM, Mortensen S, Rasmussen M, Lassaunière R, Rosenstierne MW, Polacek C, Fonager J, Cohen AS, Nielsen C, Fomsgaard A; Danish COVID-19 Genome Consortium (DCGC). Rapid and Flexible RT-qPCR Surveillance Platforms To Detect SARS-CoV-2 Mutations. Microbiol Spectr 2023;11:e0359122. [PMID: 36625603 DOI: 10.1128/spectrum.03591-22] [Reference Citation Analysis]
|
| 41 |
Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F, Maes P, Grzelak L, Prot M, Mougari S, Planchais C, Puech J, Saliba M, Sahraoui R, Fémy F, Morel N, Dufloo J, Sanjuán R, Mouquet H, André E, Hocqueloux L, Simon-Loriere E, Veyer D, Prazuck T, Péré H, Schwartz O. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. Nat Commun 2023;14:824. [PMID: 36788246 DOI: 10.1038/s41467-023-36561-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 42 |
Zeng L, Lu Y, Yan W, Yang Y. A Protein Co-Conservation Network Model Characterizes Mutation Effects on SARS-CoV-2 Spike Protein. Int J Mol Sci 2023;24. [PMID: 36834664 DOI: 10.3390/ijms24043255] [Reference Citation Analysis]
|
| 43 |
Li R, Liu H, Fairley CK, Ong JJ, Guo Y, Lu P, Zou Z, Xie L, Zhuang G, Li Y, Shen M, Zhang L. mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia. Vaccine 2023:S0264-410X(23)00126-3. [PMID: 36781332 DOI: 10.1016/j.vaccine.2023.01.075] [Reference Citation Analysis]
|
| 44 |
Nadesalingam A, Cantoni D, Aguinam ET, Chan AC, Paloniemi M, Ohlendorf L, George C, Carnell G, Lyall J, Ferrari M, Temperton N, Wagner R, Castillo-Olivares J, Baxendale H, Heeney JL. Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies. Lancet Microbe 2023;4:e58-9. [PMID: 36332646 DOI: 10.1016/S2666-5247(22)00297-X] [Reference Citation Analysis]
|
| 45 |
Han T, Luo Z, Ji L, Wu P, Li G, Liu X, Lai Y. Identification of natural compounds as SARS-CoV-2 inhibitors via molecular docking and molecular dynamic simulation. Front Microbiol 2022;13:1095068. [PMID: 36817101 DOI: 10.3389/fmicb.2022.1095068] [Reference Citation Analysis]
|
| 46 |
Tan ST, Kwan AT, Rodríguez-Barraquer I, Singer BJ, Park HJ, Lewnard JA, Sears D, Lo NC. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat Med 2023;29:358-65. [PMID: 36593393 DOI: 10.1038/s41591-022-02138-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 47 |
Plested JS, Zhu M, Cloney-Clark S, Massuda E, Patel U, Klindworth A, Massare MJ, Cai R, Fries L, Glenn G, Kalkeri R. Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation. Microorganisms 2023;11. [PMID: 36838333 DOI: 10.3390/microorganisms11020368] [Reference Citation Analysis]
|
| 48 |
Medic S, Anastassopoulou C, Lozanov-Crvenkovic Z, Dragnic N, Petrovic V, Ristic M, Pustahija T, Tsakris A, Ioannidis JPA. Incidence, Risk, and Severity of SARS-CoV-2 Reinfections in Children and Adolescents Between March 2020 and July 2022 in Serbia. JAMA Netw Open 2023;6:e2255779. [PMID: 36780157 DOI: 10.1001/jamanetworkopen.2022.55779] [Reference Citation Analysis]
|
| 49 |
Guo Y, Wang H, Xiao M, Guan X, Lei Y, Diao T, Long P, Zeng R, Lai X, Cai H, You Y, Wen Y, Li W, Wang X, Wang Y, Chen Q, Yang Y, Qiu Y, Chen J, Zeng H, Ni W, Zhao Y, Ouyang K, Wang J, Wang Q, Liu L, Song L, Wang Y, Guo H, Li X, Wu T, Yuan Y. Long-term outcomes of COVID-19 convalescents: An 18.5-month longitudinal study in Wuhan. Int J Infect Dis 2023;127:85-92. [PMID: 36509334 DOI: 10.1016/j.ijid.2022.12.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 50 |
Pei L, Chen Y, Zheng X, Gong F, Liu W, Lin J, Zheng R, Yang Z, Bi Y, Chen E. Comorbidities prolonged viral shedding of patients infected with SARS-CoV-2 omicron variant in Shanghai: A multi-center, retrospective, observational study. J Infect Public Health 2023;16:182-9. [PMID: 36566602 DOI: 10.1016/j.jiph.2022.12.003] [Reference Citation Analysis]
|
| 51 |
Shiwa-Sudo N, Sakai Y, Iwata-Yoshikawa N, Watanabe S, Yamada S, Kuroda Y, Yamamoto T, Shirakura M, Fujisaki S, Miyazaki K, Miura H, Nagata S, Fukushi S, Maeda K, Hasegawa H, Suzuki T, Nagata N. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters. J Virol 2023;97:e0136622. [PMID: 36633406 DOI: 10.1128/jvi.01366-22] [Reference Citation Analysis]
|
| 52 |
Almendro-Vázquez P, Laguna-Goya R, Paz-Artal E. Defending against SARS-CoV-2: The T cell perspective. Front Immunol 2023;14:1107803. [PMID: 36776863 DOI: 10.3389/fimmu.2023.1107803] [Reference Citation Analysis]
|
| 53 |
Kimber C, Valk SJ, Chai KL, Piechotta V, Iannizzi C, Monsef I, Wood EM, Lamikanra AA, Roberts DJ, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N. Hyperimmune immunoglobulin for people with COVID-19. Cochrane Database Syst Rev 2023;1:CD015167. [PMID: 36700518 DOI: 10.1002/14651858.CD015167.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 54 |
Lee DB, Kim H, Jeong JH, Jang US, Jang Y, Roh S, Jeon H, Kim EJ, Han SY, Maeng JY, Magez S, Radwanska M, Mun JY, Jun HS, Lee G, Song MS, Lee HR, Chung MS, Baek YH, Kim KH. Mosaic RBD nanoparticles induce intergenus cross-reactive antibodies and protect against SARS-CoV-2 challenge. Proc Natl Acad Sci U S A 2023;120:e2208425120. [PMID: 36669119 DOI: 10.1073/pnas.2208425120] [Reference Citation Analysis]
|
| 55 |
Rando HM, Lordan R, Kolla L, Sell E, Lee AJ, Wellhausen N, Naik A, Kamil JP; COVID-19 Review Consortium. The Coming of Age of Nucleic Acid Vaccines during COVID-19. ArXiv 2023. [PMID: 36263086] [Reference Citation Analysis]
|
| 56 |
Faizuloev E, Gracheva A, Korchevaya E, Smirnova D, Samoilikov R, Pankratov A, Trunova G, Khokhlova V, Ammour Y, Petrusha O, Poromov A, Leneva I, Svitich O, Zverev V. Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity. Vaccine 2023;41:892-902. [PMID: 36528447 DOI: 10.1016/j.vaccine.2022.12.019] [Reference Citation Analysis]
|
| 57 |
Ma R, Zhang Y, Zhang Y, Li X, Ji Z. The Relationship between the Transmission of Different SARS-CoV-2 Strains and Air Quality: A Case Study in China. Int J Environ Res Public Health 2023;20. [PMID: 36767307 DOI: 10.3390/ijerph20031943] [Reference Citation Analysis]
|
| 58 |
Chen B, Zhao Y, Jin Z, He D, Li H. Twice evasions of Omicron variants explain the temporal patterns in six Asian and Oceanic countries. BMC Infect Dis 2023;23:25. [PMID: 36639649 DOI: 10.1186/s12879-023-07984-9] [Reference Citation Analysis]
|
| 59 |
Cheng F, Huynh TK, Ko H, Hsueh C, Yeh Y, Wu Y, Tang C, Chen C, Tu C, Huang W, Ho C. Artemisia argyi potentially prevents the infections with SARS-CoV-2 variants.. [DOI: 10.21203/rs.3.rs-2362385/v1] [Reference Citation Analysis]
|
| 60 |
Marchini A, Petrillo M, Parrish A, Buttinger G, Tavazzi S, Querci M, Betsou F, Elsinga G, Medema G, Abdelrahman T, Gawlik B, Corbisier P. New RT-PCR Assay for the Detection of Current and Future SARS-CoV-2 Variants. Viruses 2023;15:206. [PMID: 36680246 DOI: 10.3390/v15010206] [Reference Citation Analysis]
|
| 61 |
Wen C, Liu W, He Z, Liu C. Research on emergency management of global public health emergencies driven by digital technology: A bibliometric analysis. Front Public Health 2022;10:1100401. [PMID: 36711394 DOI: 10.3389/fpubh.2022.1100401] [Reference Citation Analysis]
|
| 62 |
Zsichla L, Müller V. Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. Viruses 2023;15. [PMID: 36680215 DOI: 10.3390/v15010175] [Reference Citation Analysis]
|
| 63 |
Zheng Z, Liang W, Lin R, Hu Z, Wang Y, Lu H, Zhong W, Shen S, Pan Y. Facile Synthesis of Zinc Indium Oxide Nanofibers Distributed with Low Content of Silver for Superior Antibacterial Activity. Small Structures 2023. [DOI: 10.1002/sstr.202200291] [Reference Citation Analysis]
|
| 64 |
Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. Viruses 2023;15. [PMID: 36680207 DOI: 10.3390/v15010167] [Reference Citation Analysis]
|
| 65 |
Hadley E, Yoo YJ, Patel S, Zhou A, Laraway B, Wong R, Preiss A, Chew R, Davis H, Chute CG, Pfaff ER, Loomba J, Haendel M, Hill E, Moffitt R; N3C and RECOVER consortia. SARS-CoV-2 Reinfection is Preceded by Unique Biomarkers and Related to Initial Infection Timing and Severity: an N3C RECOVER EHR-Based Cohort Study. medRxiv 2023:2023. [PMID: 36656776 DOI: 10.1101/2023.01.03.22284042] [Reference Citation Analysis]
|
| 66 |
Holmer HK, Mackey K, Fiordalisi CV, Helfand M. Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection-Final Update of a Living, Rapid Review. Ann Intern Med 2023;176:85-91. [PMID: 36442059 DOI: 10.7326/M22-1745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 67 |
Wolf JM, Wolf LM, Bello GL, Maccari JG, Nasi LA. Molecular evolution of SARS-CoV-2 from December 2019 to August 2022. J Med Virol 2023;95:e28366. [PMID: 36458547 DOI: 10.1002/jmv.28366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 68 |
Chen SL, Jen GH, Hsu CY, Yen AM, Lai CC, Yeh YP, Chen TH. A new approach to modeling pre-symptomatic incidence and transmission time of imported COVID-19 cases evolving with SARS-CoV-2 variants. Stoch Environ Res Risk Assess 2023;37:441-52. [PMID: 36120386 DOI: 10.1007/s00477-022-02305-z] [Reference Citation Analysis]
|
| 69 |
Djordjevic M, Markovic S, Salom I, Djordjevic M. Understanding risk factors of a new variant outburst through global analysis of Omicron transmissibility. Environ Res 2023;216:114446. [PMID: 36208783 DOI: 10.1016/j.envres.2022.114446] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 70 |
Borchering RK, Mullany LC, Howerton E, Chinazzi M, Smith CP, Qin M, Reich NG, Contamin L, Levander J, Kerr J, Espino J, Hochheiser H, Lovett K, Kinsey M, Tallaksen K, Wilson S, Shin L, Lemaitre JC, Hulse JD, Kaminsky J, Lee EC, Hill AL, Davis JT, Mu K, Xiong X, Pastore Y Piontti A, Vespignani A, Srivastava A, Porebski P, Venkatramanan S, Adiga A, Lewis B, Klahn B, Outten J, Hurt B, Chen J, Mortveit H, Wilson A, Marathe M, Hoops S, Bhattacharya P, Machi D, Chen S, Paul R, Janies D, Thill JC, Galanti M, Yamana T, Pei S, Shaman J, España G, Cavany S, Moore S, Perkins A, Healy JM, Slayton RB, Johansson MA, Biggerstaff M, Shea K, Truelove SA, Runge MC, Viboud C, Lessler J. Impact of SARS-CoV-2 vaccination of children ages 5-11 years on COVID-19 disease burden and resilience to new variants in the United States, November 2021-March 2022: A multi-model study. Lancet Reg Health Am 2023;17:100398. [PMID: 36437905 DOI: 10.1016/j.lana.2022.100398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 71 |
Patel AK, Patel D, Shevkani M, Shah A, Madan S, Gohel S, Chhatwani C, Doshi A, Patel V, Sukhwani K, Kareliya H, Shah V, Savaj P, Rana M, Patel KK, Bakshi H. COVID-19 patients' clinical profile and outcome with respect to their vaccination status: A prospective observational multicentre cohort study during third wave in Western India. Indian J Med Microbiol 2023;41:28-32. [PMID: 36870745 DOI: 10.1016/j.ijmmb.2022.12.004] [Reference Citation Analysis]
|
| 72 |
Bulut H. Drug development targeting SARS-CoV-2 main protease. Glob Health Med 2022;4:296-300. [PMID: 36589216 DOI: 10.35772/ghm.2022.01066] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 73 |
Chen Y, Chen Z, Wang X, Xiong H, Shuang F, Liu X. Influencing factors of nucleic acid negative conversion in patients with mild and common COVID-19 induced by the Omicron variant of SARS-COV-2. Zhejiang Da Xue Xue Bao Yi Xue Ban 2022;51:731-7. [PMID: 36915975 DOI: 10.3724/zdxbyxb-2022-0640] [Reference Citation Analysis]
|
| 74 |
Mathez G, Pillonel T, Bertelli C, Cagno V. Alpha and Omicron SARS-CoV-2 Adaptation in an Upper Respiratory Tract Model. Viruses 2022;15. [PMID: 36680054 DOI: 10.3390/v15010013] [Reference Citation Analysis]
|
| 75 |
Simiso Sokhela, Bronwyn Bosch, Andrew Hill, Bryony Simmons, Joana Woods, Hilary Johnstone, Shabir Madhi, Ambar Qavi, Leah Ellis, Godspower Akpomiemie, Esther Bhaskar, Jacob Levi, Jonathan Falconer, Manya Mirchandani, Carmen Perez Casas, Karlien Moller, Victoria Pilkington, Toby Pepperrell, Willem Daniel Francois Venter. Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa. Open Forum Infect Dis 2022;9:ofac587. [PMID: 36540387 DOI: 10.1093/ofid/ofac587] [Reference Citation Analysis]
|
| 76 |
Wang W, Lusvarghi S, Subramanian R, Epsi NJ, Wang R, Goguet E, Fries AC, Echegaray F, Vassell R, Coggins SA, Richard SA, Lindholm DA, Mende K, Ewers EC, Larson DT, Colombo RE, Colombo CJ, Joseph JO, Rozman JS, Smith A, Lalani T, Berjohn CM, Maves RC, Jones MU, Mody R, Huprikar N, Livezey J, Saunders D, Hollis-Perry M, Wang G, Ganesan A, Simons MP, Broder CC, Tribble DR, Laing ED, Agan BK, Burgess TH, Mitre E, Pollett SD, Katzelnick LC, Weiss CD. Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history. Cell Host Microbe 2022;30:1745-1758.e7. [PMID: 36356586 DOI: 10.1016/j.chom.2022.10.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 77 |
Kumar N, Kaushik R, Singh A, Uversky VN, Zhang KYJ, Sahu U, Bhatia S, Sanyal A. Bayesian Molecular Dating Analyses Combined with Mutational Profiling Suggest an Independent Origin and Evolution of SARS-CoV-2 Omicron BA.1 and BA.2 Sub-Lineages. Viruses 2022;14. [PMID: 36560768 DOI: 10.3390/v14122764] [Reference Citation Analysis]
|
| 78 |
Li M, Wu Z, Bian X, Jiang Q, Fan S, Zhang K, Guo Z, Hui L, Guo M, Zhen F, Zhang J. Clinical and psychological status analysis of children and parents infected with familial aggregation omicron variant in Shanghai in parent-child ward. Heliyon 2022;8:e12151. [PMID: 36578400 DOI: 10.1016/j.heliyon.2022.e12151] [Reference Citation Analysis]
|
| 79 |
Liang H, Nian X, Wu J, Liu D, Feng L, Lu J, Peng Y, Zhou Z, Deng T, Liu J, Ji D, Qiu R, Lin L, Zeng Y, Xia F, Hu Y, Li T, Duan K, Li X, Wang Z, Zhang Y, Zhang H, Zhu C, Wang S, Wu X, Wang X, Li Y, Huang S, Mao M, Guo H, Yang Y, Jia R, Xufang J, Wang X, Liang S, Qiu Z, Zhang J, Ding Y, Li C, Zhang J, Fu D, He Y, Zhou D, Li C, Zhang J, Yu D, Yang XM. COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan. Cell Discov 2022;8:131. [PMID: 36494338 DOI: 10.1038/s41421-022-00496-x] [Reference Citation Analysis]
|
| 80 |
Yang C, Zhao H, Shannon CP, Tebbutt SJ. Omicron variants of SARS-CoV-2 and long COVID. Front Immunol 2022;13:1061686. [PMID: 36569883 DOI: 10.3389/fimmu.2022.1061686] [Reference Citation Analysis]
|
| 81 |
Nevejan L, Ombelet S, Laenen L, Keyaerts E, Demuyser T, Seyler L, Soetens O, Van Nedervelde E, Naesens R, Geysels D, Verstrepen W, Cattoir L, Martens S, Michel C, Mathieu E, Reynders M, Evenepoel A, Hellemans J, Vanhee M, Magerman K, Maes J, Matheeussen V, Boogaerts H, Lagrou K, Cuypers L, André E. Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts. Viruses 2022;14. [PMID: 36560741 DOI: 10.3390/v14122736] [Reference Citation Analysis]
|
| 82 |
Chatzilena A, Hyams C, Challen R, Marlow R, King J, Adegbite D, Kinney J, Clout M, Maskell N, Oliver J, Danon L, Finn A; Avon CAP Research Group. Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: A prospective test negative case-control study. Lancet Reg Health Eur 2023;25:100552. [PMID: 36506791 DOI: 10.1016/j.lanepe.2022.100552] [Reference Citation Analysis]
|
| 83 |
Montes-gonzález JA, Zaragoza-jiménez CA, Antonio-villa NE, Fermín-martínez CA, Ramírez-garcía D, Vargas-vázquez A, Gutiérrez-vargas RI, García-rodríguez G, López-gatell H, Valdés-ferrer SI, Bello-chavolla OY. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.. [DOI: 10.1101/2022.12.02.22282981] [Reference Citation Analysis]
|
| 84 |
Wiegand RE, Deng Y, Deng X, Lee A, Meyer WA 3rd, Letovsky S, Charles MD, Gundlapalli AV, MacNeil A, Hall AJ, Thornburg NJ, Jones J, Iachan R, Clarke KEN. Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022. Lancet Reg Health Am 2023;18:100403. [PMID: 36479424 DOI: 10.1016/j.lana.2022.100403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 85 |
Ojo MM, Benson TO, Peter OJ, Goufo EFD. Nonlinear optimal control strategies for a mathematical model of COVID-19 and influenza co-infection. Physica A 2022;607:128173. [PMID: 36106051 DOI: 10.1016/j.physa.2022.128173] [Cited by in Crossref: 15] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 86 |
Ramadan Abdelmoez Farahat, Abdelaziz Abdelaal, Tungki Pratama Umar, Amro A. El-Sakka, Amira Yasmine Benmelouka, Khaled Albakri, Iftikhar Ali, Tareq Al-Ahdal, Basel Abdelazeem, Ranjit Sah, Alfonso J. Rodriguez-Morales. The emergence of SARS-CoV-2 Omicron subvariants: current situation and future trends. Infez Med 2022;30. [PMID: 36482957 DOI: 10.53854/liim-3004-2] [Reference Citation Analysis]
|
| 87 |
Chen Q, Zhu K, Liu X, Zhuang C, Huang X, Huang Y, Yao X, Quan J, Lin H, Huang S, Su Y, Wu T, Zhang J, Xia N. The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. Emerg Microbes Infect 2022;11:793-803. [PMID: 35195494 DOI: 10.1080/22221751.2022.2046446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 88 |
Addai E, Zhang L, Asamoah JKK, Preko AK, Arthur YD. Fractal-fractional age-structure study of omicron SARS-CoV-2 variant transmission dynamics. Partial Differ Equ Appl Math 2022;6:100455. [PMID: 36277845 DOI: 10.1016/j.padiff.2022.100455] [Reference Citation Analysis]
|
| 89 |
Feng L, Fu S, Zhang P, Zhang Y, Zhao Y, Yao Y, Luo L, Ping P. Potential use of the S-protein-Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019. Front Public Health 2022;10:1050034. [PMID: 36518573 DOI: 10.3389/fpubh.2022.1050034] [Reference Citation Analysis]
|
| 90 |
Griewing S, Kalder M, Lingenfelder M, Wagner U, Gremke N. Impact of the COVID-19 Pandemic on Gyne-Oncological Treatment-A Retrospective Single-Center Analysis of a German University Hospital with 30,525 Patients. Healthcare (Basel) 2022;10. [PMID: 36553910 DOI: 10.3390/healthcare10122386] [Reference Citation Analysis]
|
| 91 |
Roohani J, Keikha M. Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned? World J Virol 2022; 11(6): 496-501 [DOI: 10.5501/wjv.v11.i6.496] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 92 |
Fryer HA, Hartley GE, Edwards ES, O'hehir RE, van Zelm MC. Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. Biochemical Society Transactions 2022. [DOI: 10.1042/bst20220415] [Reference Citation Analysis]
|
| 93 |
Tan ST, Kwan AT, Rodríguez-Barraquer I, Singer BJ, Park HJ, Lewnard JA, Sears D, Lo NC. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. medRxiv 2022:2022. [PMID: 36299430 DOI: 10.1101/2022.08.08.22278547] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 94 |
Granzin M, Richter S, Schrod J, Schubert N, Curtius J. Long-term Filter Efficiency of mobile Air Purifiers in Schools. Aerosol Science and Technology 2022. [DOI: 10.1080/02786826.2022.2147414] [Reference Citation Analysis]
|
| 95 |
Joseph G, Klein E, Lustig Y, Weiss-ottolenghi Y, Asraf K, Indenbaum V, Amit S, Kriger O, Gilboa M, Levy Y, Pessach IM, Kreiss Y, Regev-yochay G, Stein M. Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years. Vaccines 2022;10:1954. [DOI: 10.3390/vaccines10111954] [Reference Citation Analysis]
|
| 96 |
Noor R. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants. Viruses 2022;14. [PMID: 36423150 DOI: 10.3390/v14112541] [Reference Citation Analysis]
|
| 97 |
Chao C, Cheng D, Huang S, Chuang Y, Yeh T, Wang J. Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1023943] [Reference Citation Analysis]
|
| 98 |
Gong HR, Hu YF, Li X, Yau T, Zhang BZ, Huang JD. Non-Neutralizing Epitopes Shade Neutralizing Epitopes against Omicron in a Multiple Epitope-Based Vaccine. ACS Infect Dis 2022;8:2586-93. [PMID: 36357959 DOI: 10.1021/acsinfecdis.2c00488] [Reference Citation Analysis]
|
| 99 |
Kim J, Seo H, Kim HW, Kim D, Kwon HJ, Kim YK. Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection. Viruses 2022;14. [PMID: 36366556 DOI: 10.3390/v14112458] [Reference Citation Analysis]
|
| 100 |
Sharma S, Vercruysse T, Sanchez-Felipe L, Kerstens W, Rasulova M, Bervoets L, De Keyzer C, Abdelnabi R, Foo CS, Lemmens V, Van Looveren D, Maes P, Baele G, Weynand B, Lemey P, Neyts J, Thibaut HJ, Dallmeier K. Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters. Nat Commun 2022;13:6644. [PMID: 36333374 DOI: 10.1038/s41467-022-34439-7] [Reference Citation Analysis]
|
| 101 |
Migliara G, Renzi E, Baccolini V, Cerri A, Donia P, Massimi A, Marzuillo C, De Vito C, Casini L, Polimeni A, Gaudio E, Villari P, The Collaborating Group. Predictors of SARS-CoV-2 Infection in University Students: A Case-Control Study. Int J Environ Res Public Health 2022;19. [PMID: 36361257 DOI: 10.3390/ijerph192114376] [Reference Citation Analysis]
|
| 102 |
Atti A, Insalata F, Carr EJ, Otter AD, Castillo-Olivares J, Wu M, Harvey R, Howell M, Chan A, Lyall J, Temperton N, Cantoni D, da Costa K, Nadesalingam A, Taylor-Kerr A, Hettiarachchi N, Tranquillini C, Hewson J, Cole MJ, Foulkes S, Munro K, Monk EJM, Milligan ID, Linley E, Chand MA, Brown CS, Islam J, Semper A, Charlett A, Heeney JL, Beale R, Zambon M, Hopkins S, Brooks T, Hall V; SIREN Study Group and the Crick COVID Immunity Pipeline Consortium. Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study. J Infect 2022;85:545-56. [PMID: 36089104 DOI: 10.1016/j.jinf.2022.09.004] [Reference Citation Analysis]
|
| 103 |
Li T, Han M, Wang J, Zhou C, Mu H. Clinical characteristics and risks of the convalescent COVID-19 patients with re-detectable positive RNA test: a 430 patients with Omicron infected cross-sectional survey in Tianjin, China. Journal of Infection and Public Health 2022. [DOI: 10.1016/j.jiph.2022.11.011] [Reference Citation Analysis]
|
| 104 |
Zar HJ, MacGinty R, Workman L, Botha M, Johnson M, Hunt A, Burd T, Nicol MP, Flasche S, Quilty BJ, Goldblatt D. Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa. EClinicalMedicine 2022;53:101655. [PMID: 36128333 DOI: 10.1016/j.eclinm.2022.101655] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 105 |
Riyyan M, Sarwar HA, Chania HA, Sajid S, Hotwani S, Sarwar HU, Nawaz S, Abid S. Reactogenicity of COVID-19 Vaccines in Patients With a History of COVID-19 Infection: A Survey Conducted in Pakistan. Cureus 2022. [DOI: 10.7759/cureus.31359] [Reference Citation Analysis]
|
| 106 |
Farahat RA, Baklola M, Umar TP. Omicron B.1.1.529 subvariant: Brief evidence and future prospects. Annals of Medicine and Surgery 2022;83:104808. [DOI: 10.1016/j.amsu.2022.104808] [Reference Citation Analysis]
|
| 107 |
Peng P, Feng CQ, Hu J, He CL, Deng HJ, Fan QH, Xiang J, Tang GF, Jiang ML, Hu FY, Li F, Wang K, Tang N, Tang XP, Huang AL. Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster. iScience 2022;:105465. [PMID: 36338432 DOI: 10.1016/j.isci.2022.105465] [Reference Citation Analysis]
|
| 108 |
Takada M, Fukushima T, Ozawa S, Matsubara S, Suzuki T, Fukumoto I, Hanazawa T, Nagashima T, Uruma R, Otsuka M, Tanaka G. Infection control for COVID-19 in hospital examination room. Sci Rep 2022;12:18230. [PMID: 36309548 DOI: 10.1038/s41598-022-22643-w] [Reference Citation Analysis]
|
| 109 |
Kombe Kombe AJ, Biteghe FAN, Ndoutoume ZN, Jin T. CD8+ T-cell immune escape by SARS-CoV-2 variants of concern. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.962079] [Reference Citation Analysis]
|
| 110 |
Phan TT, Nguyen TB, Phung QT, Tran VT, Ho TT, Pho SP, Quach TH, Truong AT, Nguyen HT, Nguyen TT, Nguyen ST. Incidence of SARS-CoV-2 Infection during the Omicron Variant Emergence in Southern Vietnam: Prior Infection versus Third-Dose Vaccination. Microbiol Spectr 2022;10:e0117522. [PMID: 36000905 DOI: 10.1128/spectrum.01175-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 111 |
Sarkar MS, Madabhavi I. SARS-CoV-2 variants of concern: a review. Monaldi Arch Chest Dis 2022. [DOI: 10.4081/monaldi.2022.2337] [Reference Citation Analysis]
|
| 112 |
Pei S, Kandula S, Cascante Vega J, Yang W, Foerster S, Thompson C, Baumgartner J, Ahuja SD, Blaney K, Varma JK, Long T, Shaman J. Contact tracing reveals community transmission of COVID-19 in New York City. Nat Commun 2022;13:6307. [PMID: 36274183 DOI: 10.1038/s41467-022-34130-x] [Reference Citation Analysis]
|
| 113 |
Chassalevris T, Chaintoutis SC, Koureas M, Petala M, Moutou E, Beta C, Kyritsi M, Hadjichristodoulou C, Kostoglou M, Karapantsios T, Papadopoulos A, Papaioannou N, Dovas CI. SARS-CoV-2 wastewater monitoring using a novel PCR-based method rapidly captured the Delta-to-Omicron ΒΑ.1 transition patterns in the absence of conventional surveillance evidence. Sci Total Environ 2022;844:156932. [PMID: 35753493 DOI: 10.1016/j.scitotenv.2022.156932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 114 |
Filippatos F, Tatsi EB, Dellis C, Koukou DM, Papagiannopoulos C, Margeli A, Siahanidou T, Kanaka-Gantenbein C, Syriopoulou V, Michos A. SARS-CoV-2 seroepidemiology in paediatric population during Delta and Omicron predominance. Epidemiol Infect 2022;150:e177. [PMID: 36345855 DOI: 10.1017/S0950268822001601] [Reference Citation Analysis]
|
| 115 |
Tulimilli SV, Dallavalasa S, Basavaraju CG, Kumar Rao V, Chikkahonnaiah P, Madhunapantula SV, Veeranna RP. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Vaccines (Basel) 2022;10. [PMID: 36298616 DOI: 10.3390/vaccines10101751] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 116 |
Chen WC, Lin YP, Cheng CM, Shen CF, Li CW, Wang YK, Shih TY, Hong C, Chang TC, Shen CJ. Detection of SARS-CoV-2 Neutralizing Antibodies in Vaccinated Pregnant Women and Neonates by Using a Lateral Flow Immunoassay Coupled with a Spectrum-Based Reader. Biosensors (Basel) 2022;12. [PMID: 36291029 DOI: 10.3390/bios12100891] [Reference Citation Analysis]
|
| 117 |
Qu P, Evans JP, Kurhade C, Zeng C, Zheng YM, Xu K, Shi PY, Xie X, Liu SL. Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants. bioRxiv 2022:2022. [PMID: 36299433 DOI: 10.1101/2022.10.15.512322] [Reference Citation Analysis]
|
| 118 |
Duty JA, Kraus T, Zhou H, Zhang Y, Shaabani N, Yildiz S, Du N, Singh A, Miorin L, Li D, Stegman K, Ophir S, Cao X, Atanasoff K, Lim R, Mena I, Bouvier NM, Kowdle S, Carreño JM, Rivero-Nava L, Raskin A, Moreno E, Johnson S, Rathnasinghe R, Pai CI, Kehrer T, Cabral EP, Jangra S, Healy L, Singh G, Warang P, Simon V, Sordillo EM, van Bakel H, Liu Y, Sun W, Kerwin L, Teijaro J, Schotsaert M, Krammer F, Bresson D, García-Sastre A, Fu Y, Lee B, Powers C, Moran T, Ji H, Tortorella D, Allen R. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants. Med (N Y) 2022;3:705-721.e11. [PMID: 36044897 DOI: 10.1016/j.medj.2022.08.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 119 |
Smith DK, Lauro K, Kelly D, Fish J, Lintelman E, McEwen D, Smith C, Stecz M, Ambagaspitiya TD, Chen J. Teaching undergraduate physical chemistry lab with kinetic analysis of COVID-19 in the United States. J Chem Educ 2022;99:3471-7. [PMID: 36589277 DOI: 10.1021/acs.jchemed.2c00416] [Reference Citation Analysis]
|
| 120 |
Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, Sutherland A, Montefiori DC, Girard B, Edwards DK, Feng J, Zhou H, Baden LR, Miller JM, Das R. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N Engl J Med 2022;387:1279-91. [PMID: 36112399 DOI: 10.1056/NEJMoa2208343] [Cited by in Crossref: 121] [Cited by in F6Publishing: 18] [Article Influence: 121.0] [Reference Citation Analysis]
|
| 121 |
Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome MJ, Amoako DG, Everatt J, Bhiman JN, Scheepers C, Tebeila N, Chiwandire N, du Plessis M, Govender N, Ismail A, Glass A, Mlisana K, Stevens W, Treurnicht FK, Subramoney K, Makatini Z, Hsiao NY, Parboosing R, Wadula J, Hussey H, Davies MA, Boulle A, von Gottberg A, Cohen C. Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. Nat Commun 2022;13:5860. [PMID: 36195617 DOI: 10.1038/s41467-022-33614-0] [Reference Citation Analysis]
|
| 122 |
Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Gilca R, Ouakki M, Barkati S, Fafard J, Talbot D, Gilca V, Deceuninck G, Garenc C, Carignan A, De Wals P, De Serres G. Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada. JAMA Netw Open 2022;5:e2236670. [PMID: 36239934 DOI: 10.1001/jamanetworkopen.2022.36670] [Cited by in Crossref: 12] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 123 |
Hvidt AK, Baerends EAM, Søgaard OS, Stærke NB, Raben D, Reekie J, Nielsen H, Johansen IS, Wiese L, Benfield TL, Iversen KK, Mustafa AB, Juhl MR, Petersen KT, Ostrowski SR, Lindvig SO, Rasmussen LD, Schleimann MH, Andersen SD, Juhl AK, Dietz LL, Andreasen SR, Lundgren J, Østergaard L, Tolstrup M; ENFORCE Study Group. Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines. Front Med (Lausanne) 2022;9:994160. [PMID: 36262278 DOI: 10.3389/fmed.2022.994160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 124 |
Delshad M, Sanaei MJ, Pourbagheri-Sigaroodi A, Bashash D. Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. Int Immunopharmacol 2022;111:109128. [PMID: 35963158 DOI: 10.1016/j.intimp.2022.109128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 125 |
Ruff J, Zhang Y, Kappel M, Rathi S, Watkins K, Zhang L, Lockett C. Rapid Increase in Suspected SARS-CoV-2 Reinfections, Clark County, Nevada, USA, December 2021. Emerg Infect Dis 2022;28:1977-81. [PMID: 35969420 DOI: 10.3201/eid2810.221045] [Reference Citation Analysis]
|
| 126 |
Erikstrup C, Laksafoss AD, Gladov J, Kaspersen KA, Mikkelsen S, Hindhede L, Boldsen JK, Jørgensen SW, Ethelberg S, Holm DK, Bruun MT, Nissen J, Schwinn M, Brodersen T, Mikkelsen C, Sækmose SG, Sørensen E, Harritshøj LH, Aagaard B, Dinh KM, Busch MP, Jørgensen CS, Krause TG, Ullum H, Ostrowski SR, Espenhain L, Pedersen OBV. Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study. The Lancet Regional Health - Europe 2022;21:100479. [DOI: 10.1016/j.lanepe.2022.100479] [Reference Citation Analysis]
|
| 127 |
Park T, Hwang H, Moon S, Kang SG, Song S, Kim YH, Kim H, Ko EJ, Yoon SD, Kang SM, Hwang HS. Vaccines against SARS-CoV-2 variants and future pandemics. Expert Rev Vaccines 2022;21:1363-76. [PMID: 35924678 DOI: 10.1080/14760584.2022.2110075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 128 |
Almadhi M, Alsayyad AS, Conroy R, Atkin S, Awadhi AA, Al-Tawfiq JA, AlQahtani M. Epidemiological assessment of SARS-CoV-2 reinfection. Int J Infect Dis 2022;123:9-16. [PMID: 35931371 DOI: 10.1016/j.ijid.2022.07.075] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 129 |
Kaya G, Altindiş M. Virological, Epidemiological Features and Prevention of SARS-CoV-2 Omicron (B.1.1.529) Variant: A Rewiev. KOU Sag Bil Derg 2022. [DOI: 10.30934/kusbed.1060956] [Reference Citation Analysis]
|
| 130 |
Panthakkan A, Anzar S, Al Mansoori S, Mansoor W, Al Ahmad H. A systematic comparison of transfer learning models for COVID-19 prediction. IDT 2022;16:557-574. [DOI: 10.3233/idt-220017] [Reference Citation Analysis]
|
| 131 |
Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, Møller CH, Skov RL, Spiess K, Fomsgaard A, Lassaunière R, Rasmussen M, Stegger M, Nielsen C, Sieber RN, Cohen AS, Møller FT, Overvad M, Mølbak K, Krause TG, Kirkeby CT. Household transmission of the SARS-CoV-2 Omicron variant in Denmark. Nat Commun 2022;13:5573. [PMID: 36151099 DOI: 10.1038/s41467-022-33328-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 132 |
Scurr MJ, Lippiatt G, Capitani L, Bentley K, Lauder SN, Smart K, Somerville MS, Rees T, Stanton RJ, Gallimore A, Hindley JP, Godkin A. Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nat Commun 2022;13:5422. [PMID: 36130936 DOI: 10.1038/s41467-022-32985-8] [Reference Citation Analysis]
|
| 133 |
Gan L, Chen Y, Tan J, Wang X, Zhang D. Does potential antibody-dependent enhancement occur during SARS-CoV-2 infection after natural infection or vaccination? A meta-analysis. BMC Infect Dis 2022;22:742. [PMID: 36123623 DOI: 10.1186/s12879-022-07735-2] [Reference Citation Analysis]
|
| 134 |
He C, Yang J, Hong W, Chen Z, Peng D, Lei H, Alu A, He X, Bi Z, Jiang X, Jia G, Yang Y, Zhou Y, Yu W, Tang C, Huang Q, Yang M, Li B, Li J, Wang J, Que H, Chen L, Ren W, Wan D, Li J, Wang W, Shen G, Zhao Z, Yang L, Yang J, Wang Z, Su Z, Wei Y, Cen X, Tanaka Y, Song X, Lu S, Peng X, Lu G, Wei X. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-33209-9] [Reference Citation Analysis]
|
| 135 |
Chaouat AE, Brizic I, Kucan Brlic P, Atari N, Kliker L, Alfi O, Mandelboim M, Wolf D, Tafish L, Kol I, Jonjic S, Mandelboim O. Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern. iScience 2022;25:104935. [PMID: 35992307 DOI: 10.1016/j.isci.2022.104935] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 136 |
El-Menyar A, Khan NA, Mekkodathil A, Rizoli S, Consunji R, Elmenyar E, Galwankar S, Al-Thani H. A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time? Medicine (Baltimore) 2022;101:e30609. [PMID: 36123868 DOI: 10.1097/MD.0000000000030609] [Reference Citation Analysis]
|
| 137 |
Liang HY, Wu Y, Yau V, Yin HX, Lowe S, Bentley R, Ahmed MA, Zhao W, Sun C. SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. Vaccines (Basel) 2022;10:1538. [PMID: 36146616 DOI: 10.3390/vaccines10091538] [Reference Citation Analysis]
|
| 138 |
Ke H, Chang MR, Marasco WA. Immune Evasion of SARS-CoV-2 Omicron Subvariants. Vaccines (Basel) 2022;10:1545. [PMID: 36146623 DOI: 10.3390/vaccines10091545] [Reference Citation Analysis]
|
| 139 |
Burkholz S, Rubsamen M, Blankenberg L, Carback RT, Mochly-rosen D, Harris PE. Increasing Cases of SARS-CoV-2 Omicron Reinfection Reveals Ineffective Post-COVID-19 Immunity in Denmark and Conveys the Need for Continued Next-Generation Sequencing.. [DOI: 10.1101/2022.09.13.22279912] [Reference Citation Analysis]
|
| 140 |
Garcia-knight M, Anglin K, Tassetto M, Lu S, Zhang A, Goldberg SA, Catching A, Davidson MC, Shak JR, Romero M, Pineda-ramirez J, Diaz-sanchez R, Rugart P, Donohue K, Massachi J, Sans HM, Djomaleu M, Mathur S, Servellita V, Mcilwain D, Gaudiliere B, Chen J, Martinez EO, Tavs JM, Bronstone G, Weiss J, Watson JT, Briggs-hagen M, Abedi GR, Rutherford GW, Deeks SG, Chiu C, Saydah S, Peluso MJ, Midgley CM, Martin JN, Andino R, Kelly JD. Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study. PLoS Pathog 2022;18:e1010802. [DOI: 10.1371/journal.ppat.1010802] [Reference Citation Analysis]
|
| 141 |
Lee C, Mangalaganesh S, Wilson LOW, Kuiper MJ, Drew TW, Vasan SS. Tracking Co-Occurrence of N501Y, P681R, and Other Key Mutations in SARS-CoV-2 Spike for Surveillance. Zoonotic Diseases 2022;2:147-162. [DOI: 10.3390/zoonoticdis2030014] [Reference Citation Analysis]
|
| 142 |
Kneidinger N, Hecker M, Bessa V, Hettich I, Wald A, Wege S, Nolde AB, Oldigs M, Syunyaeva Z, Wilkens H, Gottlieb J. Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study. Infection 2022. [PMID: 36083405 DOI: 10.1007/s15010-022-01914-8] [Reference Citation Analysis]
|
| 143 |
Venkatakrishnan AJ, Anand P, Lenehan PJ, Suratekar R, Raghunathan B, Niesen MJM, Soundararajan V. On the Origins of Omicron's Unique Spike Gene Insertion. Vaccines (Basel) 2022;10. [PMID: 36146586 DOI: 10.3390/vaccines10091509] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 144 |
Guevara R, Prado-vivar B, Márquez S, Muñoz EB, Carvajal M, Guadalupe JJ, Becerra-wong M, Proaño S, Bayas-rea R, Coloma J, Grunauer M, Trueba G, Rojas-silva P, Barragán V, Cárdenas P. Occurrence of SARS-CoV-2 reinfections at regular intervals in Ecuador. Front Cell Infect Microbiol 2022;12:951383. [DOI: 10.3389/fcimb.2022.951383] [Reference Citation Analysis]
|
| 145 |
Khan SA, Khan A, Zia K, Shawish I, Barakat A, Ul-haq Z. Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein. IJMS 2022;23:10315. [DOI: 10.3390/ijms231810315] [Reference Citation Analysis]
|
| 146 |
Weil AA, Luiten KG, Casto AM, Bennett JC, O'Hanlon J, Han PD, Gamboa LS, McDermot E, Truong M, Gottlieb GS, Acker Z, Wolf CR, Magedson A, Chow EJ, Lo NK, Pothan LC, McDonald D, Wright TC, McCaffrey KM, Figgins MD, Englund JA, Boeckh M, Lockwood CM, Nickerson DA, Shendure J, Bedford T, Hughes JP, Starita LM, Chu HY. Genomic surveillance of SARS-CoV-2 Omicron variants on a university campus. Nat Commun 2022;13:5240. [PMID: 36068236 DOI: 10.1038/s41467-022-32786-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 147 |
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Kalikawe R, Datwani S, Waterworth R, Umviligihozo G, Ennis S, Young L, Dong W, Kirkby D, Burns L, Leung V, Holmes DT, Demarco ML, Simons J, Matic N, Montaner JS, Brumme CJ, Prystajecky N, Niikura M, Lowe CF, Romney MG, Brockman MA, Brumme ZL. Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination. Front Immunol 2022;13:947021. [DOI: 10.3389/fimmu.2022.947021] [Reference Citation Analysis]
|
| 148 |
Febres GL, Gershenson C. A Deterministic–Statistical Hybrid Forecast Model: The Future of the COVID-19 Contagious Process in Several Regions of Mexico. Systems 2022;10:138. [DOI: 10.3390/systems10050138] [Reference Citation Analysis]
|
| 149 |
Yang SL, Teh HS, Suah JL, Husin M, Hwong WY. SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period. The Lancet Regional Health - Western Pacific 2022;26:100572. [DOI: 10.1016/j.lanwpc.2022.100572] [Reference Citation Analysis]
|
| 150 |
Medić S, Anastassopoulou C, Lozanov-crvenković Z, Vuković V, Dragnić N, Petrović V, Ristić M, Pustahija T, Gojković Z, Tsakris A, Ioannidis JP. Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: A population-level observational study. The Lancet Regional Health - Europe 2022;20:100453. [DOI: 10.1016/j.lanepe.2022.100453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 151 |
Yang C, Zhao H, Tebbutt SJ. A glimpse into long COVID and symptoms. The Lancet Respiratory Medicine 2022;10:e81. [DOI: 10.1016/s2213-2600(22)00217-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 152 |
Xu A, Hong B, Lou F, Wang S, Li W, Shafqat A, An X, Zhao Y, Song L, Tong Y, Fan H. Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention. MedComm 2022;3. [DOI: 10.1002/mco2.172] [Reference Citation Analysis]
|
| 153 |
Al-Otaiby M, Krissaane I, Al Seraihi A, Alshenaifi J, Qahtani MH, Aljeri T, Zaatari E, Hassanain M, Algwizani A, Albarrag A, Al-Mozaini M, Alabdulaali M. SARS-CoV-2 Reinfection Rate and Outcomes in Saudi Arabia: A National Retrospective Study. Int J Infect Dis 2022;122:758-66. [PMID: 35840098 DOI: 10.1016/j.ijid.2022.07.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 154 |
Michlmayr D, Hansen CH, Gubbels SM, Valentiner-Branth P, Bager P, Obel N, Drewes B, Møller CH, Møller FT, Legarth R, Mølbak K, Ethelberg S. Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data. Lancet Reg Health Eur 2022;20:100452. [PMID: 35791335 DOI: 10.1016/j.lanepe.2022.100452] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 155 |
Dias VMDCH, Oliveira AF, Marinho AKBB, Santos Ferreira CED, Domingues CEF, Fortaleza CMCB, Vidal CFDL, Carrilho CMDDM, Pinheiro DOBP, de Assis DB, Medeiros EA, Morejón KML, Weissmann L, Michelin L, Carneiro M, Nogueira MDSDP, de Oliveira PRD, Buralli RJ, Stucchi RSB, Lins RS, Costa SF, Chebabo A. COVID-19 and isolation: Risks and implications in the scenario of new variants. The Brazilian Journal of Infectious Diseases 2022;26:102703. [DOI: 10.1016/j.bjid.2022.102703] [Reference Citation Analysis]
|
| 156 |
Petersen MS, Í Kongsstovu S, Eliasen EH, Larsen S, Hansen JL, Vest N, Dahl MM, Christiansen DH, Møller LF, Kristiansen MF. Clinical characteristics of the Omicron variant - results from a Nationwide Symptoms Survey in the Faroe Islands. Int J Infect Dis 2022;122:636-43. [PMID: 35811082 DOI: 10.1016/j.ijid.2022.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 157 |
Seid AG, Yirko T, Sayeed S, Plipat N. Infection with SARS-CoV-2 Omicron Variant 24 Days after Non-Omicron Infection, Pennsylvania, USA. Emerg Infect Dis 2022;28:1911-3. [PMID: 35914519 DOI: 10.3201/eid2809.220539] [Reference Citation Analysis]
|
| 158 |
Bartsch YC, Atyeo C, Kang J, Cai Y, Chen B, Gray KJ, Edlow AG, Alter G. Preserved recognition of Omicron spike following COVID-19 messenger RNA vaccination in pregnancy. Am J Obstet Gynecol 2022;227:493.e1-7. [PMID: 35430229 DOI: 10.1016/j.ajog.2022.04.009] [Reference Citation Analysis]
|
| 159 |
Shiwa-sudo N, Sakai Y, Iwata-yoshikawa N, Watanabe S, Yamada S, Kuroda Y, Yamamoto T, Shirakura M, Fujisaki S, Miyazaki K, Miura H, Nagata S, Fukushi S, Maeda K, Hasegawa H, Suzuki T, Nagata N. Impact of reinfection with SARS-CoV-2 Omicron variants in previously infected hamsters.. [DOI: 10.1101/2022.08.30.505966] [Reference Citation Analysis]
|
| 160 |
Safont G, Latorre I, Villar-hernández R, Stojanovic Z, Marín A, Pérez-cano C, Lacoma A, Molina-moya B, Solis AJ, Arméstar F, Matllo J, Díaz-fernández S, Cendón A, Sokalchuk L, Tolosa G, Casas I, Rosell A, Domínguez J. Measuring T-Cell Responses against SARS-CoV-2 Is of Utility for Disease and Vaccination Management. JCM 2022;11:5103. [DOI: 10.3390/jcm11175103] [Reference Citation Analysis]
|
| 161 |
Al-humaidi JY, Shaaban MM, Rezki N, Aouad MR, Zakaria M, Jaremko M, Hagar M, Elwakil BH. 1,2,3-Triazole-Benzofused Molecular Conjugates as Potential Antiviral Agents against SARS-CoV-2 Virus Variants. Life 2022;12:1341. [DOI: 10.3390/life12091341] [Reference Citation Analysis]
|
| 162 |
Meyer-rath G, Hounsell RA, Pulliam JR, Jamieson L, Nichols BE, Moultrie H, Silal SP. The Role of Modelling and Analytics in South African COVID-19 Planning and Budgeting.. [DOI: 10.1101/2022.08.23.22279123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 163 |
Kotov I, Saenko V, Borisova N, Kolesnikov A, Kondrasheva L, Tivanova E, Khafizov K, Akimkin V. Effective Approaches to Study the Genetic Variability of SARS-CoV-2. Viruses 2022;14:1855. [DOI: 10.3390/v14091855] [Reference Citation Analysis]
|
| 164 |
Wegrzynska K, Komiazyk M, Walory J, Kozinska A, Wasko I, Baraniak A. Differentiation of SARS-CoV-2 Variants Using RT-qPCRs by Targeting Recurrent Mutation Sites: A Diagnostic Laboratory Experience from Multi-Center Regional Study, August 2020-December 2021, Poland. Int J Mol Sci 2022;23. [PMID: 36012683 DOI: 10.3390/ijms23169416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 165 |
Gladkikh A, Dedkov V, Sharova A, Klyuchnikova E, Sbarzaglia V, Arbuzova T, Forghani M, Ramsay E, Dolgova A, Shabalina A, Tsyganova N, Totolian A. Uninvited Guest: Arrival and Dissemination of Omicron Lineage SARS-CoV-2 in St. Petersburg, Russia. Microorganisms 2022;10:1676. [PMID: 36014093 DOI: 10.3390/microorganisms10081676] [Reference Citation Analysis]
|
| 166 |
Horchani M, Heise NV, Csuk R, Ben Jannet H, Harrath AH, Romdhane A. Synthesis and In Silico Docking Study towards M-Pro of Novel Heterocyclic Compounds Derived from Pyrazolopyrimidinone as Putative SARS-CoV-2 Inhibitors. Molecules 2022;27:5303. [PMID: 36014537 DOI: 10.3390/molecules27165303] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 167 |
Huang X, Kon E, Han X, Zhang X, Kong N, Mitchell MJ, Peer D, Tao W. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat Nanotechnol 2022. [PMID: 35982317 DOI: 10.1038/s41565-022-01174-5] [Reference Citation Analysis]
|
| 168 |
Nadig M, Niesen MJ, Lenehan P, Agarwal V, Ross J, Ardhanari S, Venkatakrishnan A, Soundararajan V. Individuals with recent prior SARS-CoV-2 infection are at reduced risk of Omicron infection and associated hospitalization.. [DOI: 10.1101/2022.08.10.22278641] [Reference Citation Analysis]
|
| 169 |
Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, Wilairatana P. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2? Biomed Pharmacother 2022;154:113522. [PMID: 36030585 DOI: 10.1016/j.biopha.2022.113522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 170 |
Evans JP, Zeng C, Qu P, Faraone J, Zheng YM, Carlin C, Bednash JS, Zhou T, Lozanski G, Mallampalli R, Saif LJ, Oltz EM, Mohler PJ, Xu K, Gumina RJ, Liu SL. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. Cell Host Microbe 2022;30:1093-1102.e3. [PMID: 35526534 DOI: 10.1016/j.chom.2022.04.014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 52.0] [Reference Citation Analysis]
|
| 171 |
Bekliz M, Adea K, Puhach O, Perez-Rodriguez F, Marques Melancia S, Baggio S, Corvaglia AR, Jacquerioz F, Alvarez C, Essaidi-Laziosi M, Escadafal C, Kaiser L, Eckerle I. Analytical Sensitivity of Eight Different SARS-CoV-2 Antigen-Detecting Rapid Tests for Omicron-BA.1 Variant. Microbiol Spectr 2022;:e0085322. [PMID: 35938792 DOI: 10.1128/spectrum.00853-22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 172 |
Ouyang J, Zaongo SD, Harypursat V, Li X, Routy JP, Chen Y. SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. Front Public Health 2022;10:945448. [PMID: 36003629 DOI: 10.3389/fpubh.2022.945448] [Reference Citation Analysis]
|
| 173 |
Terada M, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, Hisada T, Uemoto Y, Akiko Kato, Yamanaka N, Sugiura H, Mita K, Wada A, Takahashi E, Saito K, Yoshioka R, Toyama T. Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study. Breast Cancer Res Treat 2022. [PMID: 35941421 DOI: 10.1007/s10549-022-06693-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 174 |
Sharif N, Alzahrani KJ, Ahmed SN, Khan A, Banjer HJ, Alzahrani FM, Parvez AK, Dey SK. Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019-2022. PLoS One 2022;17:e0271074. [PMID: 35913920 DOI: 10.1371/journal.pone.0271074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 175 |
Hawman DW, Meade-White K, Clancy C, Archer J, Hinkley T, Leventhal SS, Rao D, Stamper A, Lewis M, Rosenke R, Krieger K, Randall S, Khandhar AP, Hao L, Hsiang TY, Greninger AL, Gale M Jr, Berglund P, Fuller DH, Rosenke K, Feldmann H, Erasmus JH. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine. EBioMedicine 2022;83:104196. [PMID: 35932641 DOI: 10.1016/j.ebiom.2022.104196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 176 |
Yang W, Shaman JL. COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron). eLife 2022;11:e78933. [DOI: 10.7554/elife.78933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 177 |
Yuan M, Chen X, Zhu Y, Dong X, Liu Y, Qian Z, Ye L, Liu P. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. J Virol 2022;:e0077522. [PMID: 35916510 DOI: 10.1128/jvi.00775-22] [Reference Citation Analysis]
|
| 178 |
Wei H, Zhang C, Du X, Zhang Z. Research progress of biosensors for detection of SARS-CoV-2 variants based on ACE2. Talanta 2022. [DOI: 10.1016/j.talanta.2022.123813] [Reference Citation Analysis]
|
| 179 |
Duerr R, Dimartino D, Marier C, Zappile P, Levine S, Francois F, Iturrate E, Wang G, Dittmann M, Lighter J, Elbel B, Troxel AB, Goldfeld KS, Heguy A. Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York. eBioMedicine 2022;82:104141. [DOI: 10.1016/j.ebiom.2022.104141] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 180 |
Nevejan L, Cuypers L, Laenen L, Van Loo L, Vermeulen F, Wollants E, Van Hecke I, Desmet S, Lagrou K, Maes P, André E. Early SARS-CoV-2 Reinfections within 60 Days and Implications for Retesting Policies. Emerg Infect Dis 2022;28:1729-31. [PMID: 35738346 DOI: 10.3201/eid2808.220617] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 181 |
Eythorsson E, Runolfsdottir HL, Ingvarsson RF, Sigurdsson MI, Palsson R. Rate of SARS-CoV-2 Reinfection During an Omicron Wave in Iceland. JAMA Netw Open 2022;5:e2225320. [PMID: 35921113 DOI: 10.1001/jamanetworkopen.2022.25320] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 182 |
Port JR, Yinda CK, Riopelle JC, Weishampel ZA, Saturday TA, Avanzato VA, Schulz JE, Holbrook MG, Barbian K, Perry-gottschalk R, Haddock E, Martens C, Shaia CI, Lambe T, Gilbert SC, van Doremalen N, Munster VJ. Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamsters.. [DOI: 10.1101/2022.07.29.502072] [Reference Citation Analysis]
|
| 183 |
Wines BD, Kurtovic L, Trist HM, Esparon S, Lopez E, Chappin K, Chan LJ, Mordant FL, Lee WS, Gherardin NA, Patel SK, Hartley GE, Pymm P, Cooney JP, Beeson JG, Godfrey DI, Burrell LM, van Zelm MC, Wheatley AK, Chung AW, Tham WH, Subbarao K, Kent SJ, Hogarth PM. Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2. Front Immunol 2022;13:889372. [PMID: 35967361 DOI: 10.3389/fimmu.2022.889372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 184 |
Dub T, Solastie A, Hagberg L, Liedes O, Nohynek H, Haveri A, Virta C, Vara S, Lasander M, Ekström N, Österlund P, Lind K, Valtonen H, Hemmilä H, Ikonen N, Lukkarinen T, Palmu AA, Melin M. High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020–2021. Front Med 2022;9. [DOI: 10.3389/fmed.2022.876532] [Reference Citation Analysis]
|
| 185 |
Yan B, Yuan S, Cao J, Fung K, Lai PM, Yin F, Sze KH, Qin Z, Xie Y, Ye ZW, Yuen TT, Chik KK, Tsang JO, Zou Z, Chan CC, Luo C, Cai JP, Chan KH, Chung TW, Tam AR, Chu H, Jin DY, Hung IF, Yuen KY, Kao RY, Chan JF. Phosphatidic acid phosphatase 1 impairs SARS-CoV-2 replication by affecting the glycerophospholipid metabolism pathway. Int J Biol Sci 2022;18:4744-55. [PMID: 35874954 DOI: 10.7150/ijbs.73057] [Reference Citation Analysis]
|
| 186 |
Pei S, Kandula S, Vega JC, Yang W, Foerster S, Thompson C, Baumgartner J, Ahuja S, Blaney K, Varma J, Long T, Shaman J. Contact tracing reveals community transmission of COVID-19 in New York City. Res Sq 2022:rs. [PMID: 35923312 DOI: 10.21203/rs.3.rs-1840065/v1] [Reference Citation Analysis]
|
| 187 |
Li Q, Zhang L, Liang Z, Wang N, Liu S, Li T, Yu Y, Cui Q, Wu X, Nie J, Wu J, Cui Z, Lu Q, Wang X, Huang W, Wang Y. Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses. Signal Transduct Target Ther 2022;7:256. [PMID: 35896529 DOI: 10.1038/s41392-022-01123-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 188 |
Li H, Zhao X, Li J, Zheng H, Zhao Y, Yang J, Zhou J, Yang F, Chen Y, Zuo Y, Lai Q, Long H, Li Y, Jin W, Shi H, Liu L. Nasal Mucosa Exploited by SARS-CoV-2 for Replicating and Shedding during Reinfection. Viruses 2022;14:1608. [PMID: 35893674 DOI: 10.3390/v14081608] [Reference Citation Analysis]
|
| 189 |
Meyer M, Ruebsteck E, Dewald F, Klein F, Lehmann C, Huenseler C, Weber LT. Clinical Aspects of the Subsequent SARS-CoV-2 Waves in Children from 2020 to 2022-Data from a Local Cohort in Cologne, Germany (n = 21,635). Viruses 2022;14:1607. [PMID: 35893673 DOI: 10.3390/v14081607] [Reference Citation Analysis]
|
| 190 |
Bingham J, Tempia S, Moultrie H, Viboud C, Jassat W, Cohen C, Pulliam JR. Estimating the time-varying reproduction number for COVID-19 in South Africa during the first four waves using multiple measures of incidence for public and private sectors across four waves.. [DOI: 10.1101/2022.07.22.22277932] [Reference Citation Analysis]
|
| 191 |
Yan LN, Zhao ZX, Wang ZD, Xiao X, Liu PP, Zhang WK, Gu XL, Li B, Yu LP, Yu XJ. Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China. Expert Rev Vaccines 2022. [PMID: 35861138 DOI: 10.1080/14760584.2022.2104714] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 192 |
Pople D, Monk EJM, Evans S, Foulkes S, Islam J, Wellington E, Atti A, Hope R, Robotham J, Hopkins S, Brown CS, Hall VJ; SIREN Study Group. Burden of SARS-CoV-2 infection in healthcare workers during second wave in England and impact of vaccines: prospective multicentre cohort study (SIREN) and mathematical model. BMJ 2022;378:e070379. [PMID: 35858689 DOI: 10.1136/bmj-2022-070379] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 193 |
Chen J, Xu W, Li L, Yi L, Jiang Y, Hao P, Xu Z, Zou W, Li P, Gao Z, Tian M, Jin N, Ren L, Li C. Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins. Front Cell Infect Microbiol 2022;12:967493. [DOI: 10.3389/fcimb.2022.967493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 194 |
Madhi SA, Kwatra G, Myers JE, Jassat W, Dhar N, Mukendi CK, Blumberg L, Welch R, Izu A, Mutevedzi PC. SARS-CoV-2 infections during Omicron (BA.1) dominant wave and subsequent population immunity in Gauteng, South Africa.. [DOI: 10.1101/2022.07.13.22277575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 195 |
da Silva ES, Kohnen M, Gilson G, Staub T, Arendt V, Hilger C, Servais J, Charpentier E, Domingues O, Snoeck CJ, Ollert M, Seguin-devaux C, Perez-bercoff D. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. IJMS 2022;23:7675. [DOI: 10.3390/ijms23147675] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 196 |
Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, Metzler M, Kohmer N, Hoehl S, Marschalek R, Herrmann E, Helfritz FA, Wolf T, Goetsch U, Ciesek S. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. EBioMedicine 2022;82:104158. [PMID: 35834885 DOI: 10.1016/j.ebiom.2022.104158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 197 |
Liu X, Yan W, Lu T, Han Y, Lu L. Longitudinal Abnormalities in Brain Structure in COVID-19 Patients. Neurosci Bull 2022;38:1608-12. [PMID: 35794292 DOI: 10.1007/s12264-022-00913-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 198 |
Wang W, Lusvarghi S, Subramanian R, Epsi NJ, Wang R, Goguet E, Fries AC, Echegaray F, Vassell R, Coggins S, Richard SA, Lindholm DA, Mende K, Ewers E, Larson D, Colombo RE, Colombo C, Joseph JO, Rozman J, Smith A, Lalani T, Berjohn C, Maves R, Jones M, Mody R, Huprikar N, Livezey J, Saunders D, Hollis-perry M, Wang G, Ganesan A, Simons MP, Broder CC, Tribble D, Laing ED, Agan B, Burgess TH, Mitre E, Pollett SD, Katzelnick LC, Weiss CD. Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection.. [DOI: 10.1101/2022.07.05.498883] [Reference Citation Analysis]
|
| 199 |
Sсherbak SG, Vologzhanin DA, Golota AS, Kamilova TA, Makarenko SV. Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications. Journal of Clinical Practice 2022;13:66-87. [DOI: 10.17816/clinpract106239] [Reference Citation Analysis]
|
| 200 |
Mencacci A, Gili A, Camilloni B, Bicchieraro G, Spaccapelo R, Bietta C, Stracci F. Immediate reinfection with Omicron variant after clearance of a previous SARS-CoV-2 infection. Journal of Infection and Public Health 2022. [DOI: 10.1016/j.jiph.2022.07.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 201 |
Bager P, Wohlfahrt J, Bhatt S, Stegger M, Legarth R, Møller CH, Skov RL, Valentiner-Branth P, Voldstedlund M, Fischer TK, Simonsen L, Kirkby NS, Thomsen MK, Spiess K, Marving E, Larsen NB, Lillebaek T, Ullum H, Mølbak K, Krause TG; Omicron-Delta study group. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. Lancet Infect Dis 2022;22:967-76. [PMID: 35468331 DOI: 10.1016/S1473-3099(22)00154-2] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 69.0] [Reference Citation Analysis]
|
| 202 |
Kandeel M, El-Deeb W. Omicron variant receptor-binding domain phylogenetics and molecular dynamics. Comput Biol Med 2022;146:105633. [PMID: 35605487 DOI: 10.1016/j.compbiomed.2022.105633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 203 |
Dimeglio C, Migueres M, Chapuy-Regaud S, Da-Silva I, Jougla I, Pradere C, Porcheron M, Martin-Blondel G, Lougarre C, Herin F, Izopet J. Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response. J Infect 2022;85:e4-6. [PMID: 35537536 DOI: 10.1016/j.jinf.2022.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 204 |
Smolenov I, Han HH, Li P, Baccarini C, Verhoeven C, Rockhold F, Clemens SAC, Ambrosino D, Richmond P, Siber G, Liang J, Clemens R; SPECTRA Study Group. Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial. Lancet Infect Dis 2022;22:990-1001. [PMID: 35447085 DOI: 10.1016/S1473-3099(22)00144-X] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 205 |
Corbisier P, Petrillo M, Marchini A, Querci M, Buttinger G, Bekliz M, Spiess K, Polacek C, Fomsgaard A, Van den Eede G. A qualitative RT-PCR assay for the specific identification of the SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern. Journal of Clinical Virology 2022;152:105191. [DOI: 10.1016/j.jcv.2022.105191] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 206 |
Harboe ZB, Hamm SR, Pérez-Alós L, Sivapalan P, Priemé H, Wilcke T, Kjeldgaard P, Shaker S, Svorre Jordan A, Møller DL, Heftdal LD, Madsen JR, Bayarri-Olmos R, Hansen CB, Pries-Heje MM, Hasselbalch RB, Fogh K, Armenteros JJA, Hilsted L, Sørensen E, Lindegaard B, Browatzki A, Biering-Sørensen T, Frikke-Schmidt R, Ostrowski SR, Iversen KK, Bundgaard H, Nielsen SD, Garred P, Jensen JS. Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases. BMJ Open Respir Res 2022;9:e001268. [PMID: 35793836 DOI: 10.1136/bmjresp-2022-001268] [Reference Citation Analysis]
|
| 207 |
Good MK, Czarnik M, Harmon KG, Aukerman D, O'Neal CS, Day C, Goerl K, Sifre K, Fink S, Riggs MA. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Reinfections Among Fully Vaccinated and Unvaccinated University Athletes-15 States, January-November 2021. Clin Infect Dis 2022;75:S236-42. [PMID: 35771661 DOI: 10.1093/cid/ciac529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 208 |
Sun W, He L, Lou H, Fan W, Yang L, Cheng G, Liu W, Sun L. The Cross-Protective Immunity Landscape Among Different SARS-CoV-2 Variant RBDs. Front Immunol 2022;13:898520. [PMID: 35757743 DOI: 10.3389/fimmu.2022.898520] [Reference Citation Analysis]
|
| 209 |
Kremer C, Braeye T, Proesmans K, André E, Torneri A, Hens N. Serial Intervals for SARS-CoV-2 Omicron and Delta Variants, Belgium, November 19-December 31, 2021. Emerg Infect Dis 2022;28. [PMID: 35732195 DOI: 10.3201/eid2808.220220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 210 |
Bazargan M, Elahi R, Esmaeilzadeh A. OMICRON: Virology, immunopathogenesis, and laboratory diagnosis. J Gene Med 2022;:e3435. [PMID: 35726542 DOI: 10.1002/jgm.3435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 211 |
Leonardi AA, Sciuto EL, Lo Faro MJ, Morganti D, Midiri A, Spinella C, Conoci S, Irrera A, Fazio B. Molecular Fingerprinting of the Omicron Variant Genome of SARS-CoV-2 by SERS Spectroscopy. Nanomaterials 2022;12:2134. [DOI: 10.3390/nano12132134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 212 |
Li J, Wu J, Long Q, Wu Y, Hu X, He Y, Jiang M, Li J, Zhao L, Yang S, Chen X, Wang M, Zheng J, Wu F, Wu R, Ren L, Bu L, Wang H, Li K, Fu L, Zhang G, Zheng Y, Gao Z. Comprehensive Humoral and Cellular Immune Responses to SARS-CoV-2 Variants in Diverse Chinese Population. Research 2022;2022:1-9. [DOI: 10.34133/2022/9873831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 213 |
van Dorp C, Goldberg E, Ke R, Hengartner N, Romero-severson E. Global estimates of the fitness advantage of SARS-CoV-2 variant Omicron.. [DOI: 10.1101/2022.06.15.22276436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 214 |
Erazo D, Vincenti-Gonzalez MF, van Loenhout JAF, Hubin P, Vandromme M, Maes P, Taquet M, Van Weyenbergh J, Catteau L, Dellicour S. Investigating COVID-19 Vaccine Impact on the Risk of Hospitalisation through the Analysis of National Surveillance Data Collected in Belgium. Viruses 2022;14. [PMID: 35746786 DOI: 10.3390/v14061315] [Reference Citation Analysis]
|
| 215 |
Soleimanian S, Alyasin S, Sepahi N, Ghahramani Z, Kanannejad Z, Yaghobi R, Karimi MH. An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. Front Immunol 2022;13:884879. [PMID: 35669767 DOI: 10.3389/fimmu.2022.884879] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 216 |
Vargas L, Valdivieso N, Tempio F, Simon V, Sauma D, Valenzuela L, Beltrán C, Castillo-Delgado L, Contreras-Benavides X, Acevedo ML, Acevedo J, Gonzalez RI, Valiente-Echeverría F, Soto-Rifo R, Rosemblatt M, Lopez M, Osorio F, Bono MR. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. BMC Med 2022;20:216. [PMID: 35676738 DOI: 10.1186/s12916-022-02406-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 217 |
Nagarajan P, Kumar J, Howlader A, Sabapathy SK, Gopal M, Port Louis LR, Kumar S. SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS TYPE 2 OMICRON VARIANT OUTBREAK IN INDIA: TIME TO ALERT. Asian J Pharm Clin Res 2022. [DOI: 10.22159/ajpcr.2022.v15i6.44731] [Reference Citation Analysis]
|
| 218 |
Sievers C, Zacher B, Ullrich A, Huska M, Fuchs S, Buda S, Haas W, Diercke M, An der Heiden M, Kröger S. SARS-CoV-2 Omicron variants BA.1 and BA.2 both show similarly reduced disease severity of COVID-19 compared to Delta, Germany, 2021 to 2022. Euro Surveill 2022;27. [PMID: 35656831 DOI: 10.2807/1560-7917.ES.2022.27.22.2200396] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 219 |
Biancolella M, Colona VL, Mehrian-Shai R, Watt JL, Luzzatto L, Novelli G, Reichardt JKV. COVID-19 2022 update: transition of the pandemic to the endemic phase. Hum Genomics 2022;16:19. [PMID: 35650595 DOI: 10.1186/s40246-022-00392-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 220 |
Cohen LE, Spiro DJ, Viboud C. Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations. PLoS Pathog 2022;18:e1010591. [PMID: 35771775 DOI: 10.1371/journal.ppat.1010591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 221 |
Davies MA, Kassanjee R, Rousseau P, Morden E, Johnson L, Solomon W, Hsiao NY, Hussey H, Meintjes G, Paleker M, Jacobs T, Raubenheimer P, Heekes A, Dane P, Bam JL, Smith M, Preiser W, Pienaar D, Mendelson M, Naude J, Schrueder N, Mnguni A, Le Roux S, Murie K, Prozesky H, Mahomed H, Rossouw L, Wasserman S, Maughan D, Boloko L, Smith B, Taljaard J, Symons G, Ntusi NAB, Parker A, Wolter N, Jassat W, Cohen C, Lessells R, Wilkinson RJ, Arendse J, Kariem S, Moodley M, Wolmarans M, Cloete K, Boulle A; Western Cape and South African National Departments of Health in collaboration with the National Institute for Communicable Diseases in South Africa Affiliations. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. Trop Med Int Health 2022;27:564-73. [PMID: 35411997 DOI: 10.1111/tmi.13752] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 30.0] [Reference Citation Analysis]
|
| 222 |
Wong NS, Chung SL, Lee SS. The challenges of enhancing global preparedness in response to the impending Omicron pandemic. J Microbiol Immunol Infect 2022;55:549-51. [PMID: 35331664 DOI: 10.1016/j.jmii.2022.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 223 |
Shao W, Zhang W, Fang X, Yu D, Wang X. Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures. J Microbiol Immunol Infect 2022;55:387-94. [PMID: 35501267 DOI: 10.1016/j.jmii.2022.03.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 224 |
Sun K, Tempia S, Kleynhans J, von Gottberg A, McMorrow ML, Wolter N, Bhiman JN, Moyes J, du Plessis M, Carrim M, Buys A, Martinson NA, Kahn K, Tollman S, Lebina L, Wafawanaka F, du Toit JD, Gómez-Olivé FX, Mkhencele T, Viboud C, Cohen C. SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron's impact in South African population cohorts. Sci Transl Med 2022;:eabo7081. [PMID: 35638937 DOI: 10.1126/scitranslmed.abo7081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 225 |
Seo YB, Ko A, Shin D, Kim J, Suh YS, Na J, Ryu JI, Sung YC. Potentiating the cross-reactive IFN-γ T cell and polyfunctional T cell responses by heterologous GX-19N DNA booster in mice primed with either a COVID-19 mRNA vaccine or inactivated vaccine.. [DOI: 10.1101/2022.05.29.493923] [Reference Citation Analysis]
|
| 226 |
López-cortés GI, Palacios-pérez M, Veledíaz HF, Hernández-aguilar M, López-hernández GR, Zamudio GS, José MV. The Spike Protein of SARS-CoV-2 Is Adapting Because of Selective Pressures. Vaccines 2022;10:864. [DOI: 10.3390/vaccines10060864] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 227 |
So MKP, Chan JNL, Chu AMY. Dynamic Causality Analysis of COVID-19 Pandemic Risk and Oil Market Changes. JRFM 2022;15:240. [DOI: 10.3390/jrfm15060240] [Reference Citation Analysis]
|
| 228 |
Sanyaolu A, Marinkovic A, Prakash S, Haider N, Williams M, Okorie C, Badaru O, Smith S. SARS-CoV-2 Omicron variant (B.1.1.529): A concern with immune escape. World J Virol 2022; 11(3): 137-143 [DOI: 10.5501/wjv.v11.i3.137] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 229 |
Bignon E, Marazzi M, Grandemange S, Monari A. Autophagy and evasion of the immune system by SARS-CoV-2. Structural features of the non-structural protein 6 from wild type and Omicron viral strains interacting with a model lipid bilayer. Chem Sci 2022;13:6098-105. [PMID: 35685814 DOI: 10.1039/d2sc00108j] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 230 |
Lacy J, Mensah A, Simmons R, Andrews N, Siddiqui MR, Bukasa A, O'Boyle S, Campbell H, Brown K. Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England. Epidemiol Infect 2022;150:e109. [PMID: 35607808 DOI: 10.1017/S0950268822000966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 231 |
Branković J, Milovanović VM, Simijonović D, Novaković S, Petrović ZD, Trifunović SS, Bogdanović GA, Petrović VP. Pyrazolone-type compounds: synthesis and in silico assessment of antiviral potential against key viral proteins of SARS-CoV-2. RSC Adv 2022;12:16054-70. [PMID: 35733695 DOI: 10.1039/d2ra02542f] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 232 |
Bhiman JN, Moore PL. Leveraging South African HIV research to define SARS‐CoV ‐2 immunity triggered by sequential variants of concern. Immunological Reviews. [DOI: 10.1111/imr.13086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 233 |
Sacco C, Petrone D, Del Manso M, Mateo-Urdiales A, Fabiani M, Bressi M, Bella A, Pezzotti P, Rota MC, Riccardo F; Italian Integrated Surveillance of COVID-19 study group. Risk and protective factors for SARS-CoV-2 reinfections, surveillance data, Italy, August 2021 to March 2022. Euro Surveill 2022;27. [PMID: 35593164 DOI: 10.2807/1560-7917.ES.2022.27.20.2200372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 234 |
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Kalikawe R, Datwani S, Waterworth R, Umviligihozo G, Ennis S, Young L, Dong W, Kirkby D, Burns L, Leung V, Holmes DT, Demarco ML, Simons J, Matic N, Montaner JS, Brumme CJ, Prystajecky N, Niikura M, Lowe CF, Romney MG, Brockman MA, Brumme ZL. Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination.. [DOI: 10.1101/2022.05.19.22275026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 235 |
Zeng L, Liu Y, Nguyenla XH, Abbott TR, Han M, Zhu Y, Chemparathy A, Lin X, Chen X, Wang H, Rane DA, Spatz JM, Jain S, Rustagi A, Pinsky B, Zepeda AE, Kadina AP, Walker JA 3rd, Holden K, Temperton N, Cochran JR, Barron AE, Connolly MD, Blish CA, Lewis DB, Stanley SA, La Russa MF, Qi LS. Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro. Nat Commun 2022;13:2766. [PMID: 35589813 DOI: 10.1038/s41467-022-30546-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 236 |
Ma Y, Guo X, Su W, Feng Y, Han F. Dual-Path Effect of Mortality Salience Induced by COVID-19 on Food Safety Behavior in China. Int J Environ Res Public Health 2022;19:6100. [PMID: 35627635 DOI: 10.3390/ijerph19106100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 237 |
Hoffmann M, Arora P, Pöhlmann S. Understanding Omicron: Transmissibility, immune evasion and antiviral intervention. Clin Transl Med 2022;12:e839. [PMID: 35538886 DOI: 10.1002/ctm2.839] [Reference Citation Analysis]
|
| 238 |
Zelner J, Eisenberg M. Rapid response modeling of SARS-CoV-2 transmission. Science 2022;376:579-80. [PMID: 35511985 DOI: 10.1126/science.abp9498] [Reference Citation Analysis]
|
| 239 |
Manali M, Bissett LA, Amat JAR, Logan N, Scott S, Hughes EC, Harvey WT, Orton R, Thomson EC, Gunson RN, Viana M, Willett B, Murcia PR. SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity.. [DOI: 10.1101/2022.05.06.490867] [Reference Citation Analysis]
|
| 240 |
Wang B, Andraweera P, Elliott S, Mohammed H, Lassi Z, Twigger A, Borgas C, Gunasekera S, Ladhani S, Marshall HS. Asymptomatic SARS-CoV-2 infection by age: A systematic review and meta-analysis.. [DOI: 10.1101/2022.05.05.22274697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 241 |
Sendi P, Razonable RR, Nelson SB, Soriano A, Gandhi RT. First-generation Oral Antivirals Against SARS-CoV-2. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.04.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 242 |
Nel J, Venter WDF. Decoding the next SARS-CoV-2 variant. The Lancet Global Health 2022. [DOI: 10.1016/s2214-109x(22)00199-1] [Reference Citation Analysis]
|
| 243 |
Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Gilca R, Ouakki M, Barkati S, Fafard J, Talbot D, Gilca V, Deceuninck G, Garenc C, Carignan A, De Wals P, De Serres G. Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination.. [DOI: 10.1101/2022.04.29.22274455] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 244 |
Suntronwong N, Kanokudom S, Auphimai C, Assawakosri S, Thongmee T, Vichaiwattana P, Duangchinda T, Chantima W, Pakchotanon P, Chansaenroj J, Puenpa J, Nilyanimit P, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.. [DOI: 10.1101/2022.04.25.22274294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 245 |
Petrie JG, King JP, Mcclure DL, Rolfes MA, Meece JK, Belongia EA, Mclean HQ. Effectiveness of COVID-19 mRNA vaccine booster dose relative to primary series during a period of Omicron circulation.. [DOI: 10.1101/2022.04.15.22273915] [Reference Citation Analysis]
|
| 246 |
Pastorio C, Zech F, Noettger S, Jung C, Jacob T, Sparrer KM, Kirchhoff F. Determinants of Spike Infectivity, Processing and Neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2.. [DOI: 10.1101/2022.04.13.488221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 247 |
Odak I, Schultze-Florey CR, Hammerschmidt SI, Ritter C, Willenzon S, Friedrichsen M, Ravens I, Sikora R, Bayir LM, Gutierrez Jauregui R, Bernhardt G, Stankov MV, Cossmann A, Hansen G, Krey T, Cornberg M, Koenecke C, Behrens GMN, Bošnjak B, Förster R. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. Front Immunol 2022;13:863039. [PMID: 35359969 DOI: 10.3389/fimmu.2022.863039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 248 |
Choi YJ, Acharya KP. How serious is the Omicron variant? transmissibility, genomics, and responses to COVID-19 vaccines, and ‘Stealth’ Omicron variants. Life Cycle 2022;2. [DOI: 10.54724/lc.2022.e7] [Reference Citation Analysis]
|
| 249 |
Ding K, Jiang W, Xiong C, Lei M. Turning point: A new global COVID-19 wave or a signal of the beginning of the end of the global COVID-19 pandemic? Immun Inflamm Dis 2022;10:e606. [PMID: 35349754 DOI: 10.1002/iid3.606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 250 |
Methi F, Hernæs KH, Skyrud KD, Magnusson K. Pandemic trends in health care use: From the hospital bed to self-care with COVID-19. PLoS One 2022;17:e0265812. [PMID: 35320323 DOI: 10.1371/journal.pone.0265812] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 251 |
Long Q, Yang Y, Yang M, Bai H, Sun W, Yang X, Huang W, Li D, Ma Y. Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response. Nanomedicine 2022;41:102527. [PMID: 35104670 DOI: 10.1016/j.nano.2022.102527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 252 |
Koyama T, Miyakawa K, Tokumasu R, S Jeremiah S, Kudo M, Ryo A. Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2. Future Microbiol 2022;17:417-24. [PMID: 35350884 DOI: 10.2217/fmb-2022-0025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 253 |
Alkhatib M, Salpini R, Carioti L, Ambrosio FA, D'Anna S, Duca L, Costa G, Bellocchi MC, Piermatteo L, Artese A, Santoro MM, Alcaro S, Svicher V, Ceccherini-Silberstein F. Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile. Microbiol Spectr 2022;:e0273221. [PMID: 35352942 DOI: 10.1128/spectrum.02732-21] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 254 |
Vardhana S, Baldo L, Morice WG 2nd, Wherry EJ. Understanding T-cell responses to COVID-19 is essential for informing public health strategies. Sci Immunol 2022;:eabo1303. [PMID: 35324269 DOI: 10.1126/sciimmunol.abo1303] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 255 |
Chen C, Boorla VS, Chowdhury R, Nissly RH, Gontu A, Chothe SK, Labella L, Jakka P, Ramasamy S, Vandegrift KJ, Nair MS, Kuchipudi SV, Maranas CD. A CNN model for predicting binding affinity changes between SARS-CoV-2 spike RBD variants and ACE2 homologues.. [DOI: 10.1101/2022.03.22.485413] [Reference Citation Analysis]
|
| 256 |
Nguyen NN, Houhamdi L, Hoang VT, Delerce J, Delorme L, Colson P, Brouqui P, Fournier PE, Raoult D, Gautret P. SARS-CoV-2 reinfection and COVID-19 severity. Emerg Microbes Infect 2022;11:894-901. [PMID: 35264078 DOI: 10.1080/22221751.2022.2052358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 257 |
Borchering RK, Mullany LC, Howerton E, Chinazzi M, Smith CP, Qin M, Reich NG, Contamin L, Levander J, Kerr J, Espino J, Hochheiser H, Lovett K, Kinsey M, Tallaksen K, Wilson S, Shin L, Lemaitre JC, Hulse JD, Kaminsky J, Lee EC, Davis JT, Mu K, Xiong X, Piontti APY, Vespignani A, Srivastava A, Porebski P, Venkatramanan S, Adiga A, Lewis B, Klahn B, Outten J, Hurt B, Chen J, Mortveit H, Wilson A, Marathe M, Hoops S, Bhattacharya P, Machi D, Chen S, Paul R, Janies D, Thill JC, Galanti M, Yamana T, Pei S, Shaman J, Espana G, Cavany S, Moore S, Perkins A, Healy JM, Slayton RB, Johansson MA, Biggerstaff M, Shea K, Truelove SA, Runge MC, Viboud C, Lessler J. Impact of SARS-CoV-2 vaccination of children ages 5-11 years on COVID-19 disease burden and resilience to new variants in the United States, November 2021-March 2022: a multi-model study. medRxiv 2022:2022. [PMID: 35313593 DOI: 10.1101/2022.03.08.22271905] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 258 |
Yonekawa A, Shimono N. Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants including Omicron (B.1.1.529). Biology (Basel) 2022;11:400. [PMID: 35336774 DOI: 10.3390/biology11030400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 259 |
Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California.. [DOI: 10.1101/2022.01.11.22269045] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 63.0] [Reference Citation Analysis]
|
| 260 |
Peacock TP, Brown JC, Zhou J, Thakur N, Sukhova K, Newman J, Kugathasan R, Yan AW, Furnon W, De Lorenzo G, Cowton VM, Reuss D, Moshe M, Quantrill JL, Platt OK, Kaforou M, Patel AH, Palmarini M, Bailey D, Barclay WS. The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein.. [DOI: 10.1101/2021.12.31.474653] [Cited by in Crossref: 102] [Cited by in F6Publishing: 123] [Article Influence: 102.0] [Reference Citation Analysis]
|
| 261 |
Rothenberger S, Hurdiss DL, Walser M, Malvezzi F, Mayor J, Ryter S, Moreno H, Liechti N, Bosshart A, Iss C, Calabro V, Cornelius A, Hospodarsch T, Neculcea A, Looser T, Schlegel A, Fontaine S, Villemagne D, Paladino M, Schiegg D, Mangold S, Reichen C, Radom F, Kaufmann Y, Schaible D, Schlegel I, Zitt C, Sigrist G, Straumann M, Wolter J, Comby M, Sacarcelik F, Drulyte I, Lyoo H, Wang C, Li W, Du W, Binz HK, Herrup R, Lusvarghi S, Neerukonda SN, Vassell R, Wang W, Adler JM, Eschke K, Nascimento M, Abdelgawad A, Gruber AD, Bushe J, Kershaw O, Knutson CG, Balavenkatraman KK, Ramanathan K, Wyler E, Teixeira Alves LG, Lewis S, Watson R, Haeuptle MA, Zürcher A, Dawson KM, Steiner D, Weiss CD, Amstutz P, van Kuppeveld FJM, Stumpp MT, Bosch BJ, Engler O, Trimpert J. The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants. Nat Biotechnol 2022;40:1845-54. [PMID: 35864170 DOI: 10.1038/s41587-022-01382-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 262 |
Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med 2022;28:2398-405. [PMID: 36357676 DOI: 10.1038/s41591-022-02051-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 263 |
Bartha FA, Boldog P, Tekeli T, Vizi Z, Dénes A, Röst G. Potential Severity, Mitigation, and Control of Omicron Waves Depending on Pre-existing Immunity and Immune Evasion. Trends in Biomathematics: Stability and Oscillations in Environmental, Social, and Biological Models 2022. [DOI: 10.1007/978-3-031-12515-7_22] [Reference Citation Analysis]
|
| 264 |
Recio Comí G, Benavent Bofill C, Antón A, Andrés C, Gutiérrez C. Reinfección por SARS-CoV-2: infección por las variantes delta y ómicron en un periodo de 20 días. Med Lab 2022. [DOI: 10.20960/revmedlab.00141] [Reference Citation Analysis]
|
| 265 |
Macdonald GM, Longcore T. Geographic Patterns of COVID-19 Vaccination, Infection, and Mortality in the United States During Year Two of the Pandemic and the Influence of Political Orientation. Coronavirus (COVID-19) Outbreaks, Vaccination, Politics and Society 2022. [DOI: 10.1007/978-3-031-09432-3_21] [Reference Citation Analysis]
|
| 266 |
Young M, Crook H, Scott J, Edison P. Covid-19: virology, variants, and vaccines. BMJ Med 2022;1:e000040. [PMID: 36936563 DOI: 10.1136/bmjmed-2021-000040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 267 |
Idowu KA, Onyenaka C, Olaleye OA. A computational evaluation of structural stability of omicron and delta mutations of SARS-CoV-2 spike proteins and human ACE-2 interactions. Inform Med Unlocked 2022;33:101074. [PMID: 36092780 DOI: 10.1016/j.imu.2022.101074] [Reference Citation Analysis]
|
| 268 |
Rahmani S, Rezaei N. SARS-CoV-2 Omicron (B.1.1.529) Variant: No Time to Wait! Acta Biomed 2022;93:e2022097. [PMID: 35546004 DOI: 10.23750/abm.v93i2.12712] [Reference Citation Analysis]
|
| 269 |
Onishi T, Honda N, Igarashi Y. Optimal and worst testing strategies for COVID-19.. [DOI: 10.1101/2021.08.31.21262868] [Reference Citation Analysis]
|
